{
  "cache_date": "2025-11-01T11:16:48.810122",
  "data": [
    {
      "created": "2025-10-31T09:57:04.338513+00:00",
      "modified": "2025-10-31T09:57:04.577744+00:00",
      "id": 17492114,
      "conceptrecid": "17492113",
      "doi": "10.5281/zenodo.17492114",
      "conceptdoi": "10.5281/zenodo.17492113",
      "doi_url": "https://doi.org/10.5281/zenodo.17492114",
      "metadata": {
        "title": "PID:00000-Andrzej Tkacz-TEST",
        "doi": "10.5281/zenodo.17492114",
        "publication_date": "2025-10-31",
        "description": "test",
        "access_right": "open",
        "creators": [
          {
            "name": "Andrzej",
            "affiliation": "ARGOS"
          }
        ],
        "contributors": [
          {
            "name": "Andrzej Tkacz (0000-0002-0701-8946)",
            "affiliation": "orcid",
            "type": "Researcher",
            "orcid": "0000-0002-0701-8946"
          }
        ],
        "related_identifiers": [
          {
            "identifier": "https://argos.openaire.eu/explore-plans/overview/public/d59e2616-4cc8-42f2-a80d-03c1d6d2df46",
            "relation": "isIdenticalTo",
            "scheme": "url"
          }
        ],
        "version": "1",
        "resource_type": {
          "title": "Output management plan",
          "type": "publication",
          "subtype": "datamanagementplan"
        },
        "communities": [
          {
            "id": "argos"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17492113"
              }
            }
          ]
        }
      },
      "title": "PID:00000-Andrzej Tkacz-TEST",
      "links": {
        "self": "https://zenodo.org/api/records/17492114",
        "self_html": "https://zenodo.org/records/17492114",
        "preview_html": "https://zenodo.org/records/17492114?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17492114",
        "self_doi": "https://doi.org/10.5281/zenodo.17492114",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17492114",
        "reserve_doi": "https://zenodo.org/api/records/17492114/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17492113",
        "parent_html": "https://zenodo.org/records/17492113",
        "parent_doi": "https://doi.org/10.5281/zenodo.17492113",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17492113",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17492114/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17492114/sequence/default",
        "files": "https://zenodo.org/api/records/17492114/files",
        "media_files": "https://zenodo.org/api/records/17492114/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17492114:PID00000Andrzej_TkaczTEST.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17492114:PID00000Andrzej_TkaczTEST.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17492114:PID00000Andrzej_TkaczTEST.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17492114:PID00000Andrzej_TkaczTEST.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17492114:PID00000Andrzej_TkaczTEST.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17492114:PID00000Andrzej_TkaczTEST.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17492114/files-archive",
        "archive_media": "https://zenodo.org/api/records/17492114/media-files-archive",
        "latest": "https://zenodo.org/api/records/17492114/versions/latest",
        "latest_html": "https://zenodo.org/records/17492114/latest",
        "versions": "https://zenodo.org/api/records/17492114/versions",
        "draft": "https://zenodo.org/api/records/17492114/draft",
        "access_links": "https://zenodo.org/api/records/17492114/access/links",
        "access_grants": "https://zenodo.org/api/records/17492114/access/grants",
        "access_users": "https://zenodo.org/api/records/17492114/access/users",
        "access_request": "https://zenodo.org/api/records/17492114/access/request",
        "access": "https://zenodo.org/api/records/17492114/access",
        "communities": "https://zenodo.org/api/records/17492114/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17492114/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17492114/request-deletion",
        "requests": "https://zenodo.org/api/records/17492114/requests"
      },
      "updated": "2025-10-31T09:57:04.577744+00:00",
      "recid": "17492114",
      "revision": 4,
      "files": [
        {
          "id": "e3466bcd-24dc-4db3-a732-adeff477541c",
          "key": "PID00000Andrzej_TkaczTEST.json",
          "size": 1389,
          "checksum": "md5:9420a7a5ddd08962184aed7509100eab",
          "links": {
            "self": "https://zenodo.org/api/records/17492114/files/PID00000Andrzej_TkaczTEST.json/content"
          }
        },
        {
          "id": "3d0a1162-14b6-414a-9525-28ac9efe78b3",
          "key": "PID00000Andrzej_TkaczTEST.pdf",
          "size": 29499,
          "checksum": "md5:1abaaa7cbaf96bce08c6d6a45947d7da",
          "links": {
            "self": "https://zenodo.org/api/records/17492114/files/PID00000Andrzej_TkaczTEST.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "96287"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 3,
        "unique_downloads": 2,
        "views": 4,
        "unique_views": 4,
        "version_downloads": 3,
        "version_unique_downloads": 2,
        "version_unique_views": 4,
        "version_views": 4
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-29T08:31:43.584851+00:00",
      "modified": "2025-10-29T08:31:44.226533+00:00",
      "id": 17472300,
      "conceptrecid": "17472299",
      "doi": "10.3897/pharmacia.72.e170867",
      "doi_url": "https://doi.org/10.3897/pharmacia.72.e170867",
      "metadata": {
        "title": "Non-interventional pharmacovigilance studies - an analysis of real-world data sources in the HMA-EMA catalogs",
        "doi": "10.3897/pharmacia.72.e170867",
        "publication_date": "2025-10-27",
        "description": "<p>Real-world data catalogs established by the Heads of Medicines Agencies and the European Medicines Agency (HMA\u2013EMA RWD catalogues) represent a centralized digital approach for broad access to reliable data to ensure patient safety. In this study, RWD catalog analysis was conducted in order to identify best practices and challenges, focusing on finalized non-interventional studies (NISs) with a scope specified as 'safety'. The results (n = 240) show a predominance of studies required by a pharmaceutical regulator (56.6%) as well as the importance of NIS in pharmacovigilance via inclusion in risk management plans (RMPs) (52%) and broad use of NIS in risk minimization measure (RMM) evaluation. However, the lack of a unified regulatory framework, insufficient published data, and the recognized need for digital tool implementation create the necessity for improvement within the European Union (EU) pharmaceutical legislation.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Hababa-Ivanova, Ines",
            "affiliation": "Medical University-Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Getova-Kolarova, Violeta",
            "affiliation": "Medical University-Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Ivanov, Antonio",
            "affiliation": "Medical University-Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Getov, Ilko",
            "affiliation": "Medical University-Sofia, Sofia, Bulgaria"
          }
        ],
        "keywords": [
          "digitalization",
          "EMA",
          "non-interventional studies",
          "pharmacovigilance",
          "RWD"
        ],
        "related_identifiers": [
          {
            "identifier": "10.3897/pharmacia.72.e170867.figure4",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e170867.figure2",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e170867.figure1",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e170867.figure3",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.1007/s43441-023-00544-y",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1089/jpm.2008.9690",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1111/bcp.12474",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.2196/26631",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.jclinepi.2024.111341",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1007/s00270-020-02649-5",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1186/s12874-023-01855-2",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.11613/BM.2014.022",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.34172/ijhpm.2020.198",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.chest.2020.03.014",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          }
        ],
        "references": [
          "Acha V, Barefoot B, Juarez Garcia A, Lehner V, Monno R, Sandler S, Spooner A, Verpillat P (2023) Principles for Good Practice in the Conduct of Non-interventional Studies: The View of Industry Researchers. Ther Innov Regul Sci 57(6): 1199\u2013208. https://doi.org/10.1007/s43441-023-00544-y",
          "Carlson MDA, Morrison RS (2009) Study design, precision, and validity in observational studies. J Palliat Med 12(1): 77\u201382. https://doi.org/10.1089/jpm.2008.9690",
          "CIOMS (2014) Practical approaches to risk minimisation for medicinal products: Report of CIOMS Working Group IX. https://cioms.ch/sd7fdh93gewd882ds/jkdf79ds7dl092dq-purple-book/CIOMS_IX_Risk_minimisation_SECURED_20140811v8.pdf",
          "Chan EW, Liu KQL, Chui CSL, Sing CW, Wong LYL, Wong ICK (2015) Adverse drug reactions \u2013 examples of detection of rare events using databases. Br J Clin Pharmacol 80(4): 855\u2013861. https://doi.org/10.1111/bcp.12474",
          "Degun R, Patel D, Marinsek N, Chalmers M (2014) Value of rare disease non-interventional studies to support payer & clinical decision making. Value Health 17(3): A206. https://www.valueinhealthjournal.com/article/S1098-3015(14)01257-1/fulltext",
          "FDA (2018) Real-World Evidence Program. U.S. Food & Drug Administration. https://www.fda.gov/media/120060/download?attachment",
          "EMA (2024) HMA-EMA Catalogues of real-world data sources and studies. https://www.ema.europa.eu/en/news/launch-new-hma-ema-catalogues-real-world-data-sources-studies",
          "EMA (2025) Homepage. Launch of new HMA-EMA catalogues of real-world data sources and studies. https://catalogues.ema.europa.eu/",
          "EUR-Lex (2014) Regulation 536/2014 of the European Parliament and of the Council. https://eur-lex.europa.eu/eli/reg/2014/536/oj/eng",
          "ENCePP (2025) Code of Conduct. European Union. https://encepp.europa.eu/encepp-toolkit/code-conduct_en",
          "ENCePP (2025a) Discontinuation of the ENCePP Seal. European Union. https://encepp.europa.eu/newsroom/news/discontinuation-encepp-seal-2025-02-18_en",
          "Jungkunz M, K\u00f6ngeter A, Mehlis K, Winkler EC, Schickhardt C (2021) Secondary use of clinical data in data-gathering, non-interventional research or learning activities: definition, types, and a framework for risk assessment. J Med Internet Res 23(6):e26631. https://doi.org/10.2196/26631",
          "Leducq S, Zaki F, Hollestein LM, Apfelbacher C, Ponna NP, Mazmudar R, Grana S (2024) The majority of observational studies in leading peer-reviewed medicine journals are not registered and do not have a publicly accessible protocol: a scoping review. J Clin Epidemiol 170: 111341. https://doi.org/10.1016/j.jclinepi.2024.111341",
          "Pereira PL, Helmberger T, Taieb J, Vilgrain V, de Baere T (2020) Scientific societies should start sponsoring observational studies. Cardiovasc Intervent Radiol 43(12): 1865\u20131867. https://doi.org/10.1007/s00270-020-02649-5",
          "Schneider A, Wagenknecht A, Sydow H, Riedlinger D, Holzinger F, Figura A, Deutschbein J, Reinhold T, Pigorsch M, Stasun U, Schenk L, M\u00f6ckel M (2023) Primary and secondary data in emergency medicine health services research \u2013 a comparative analysis in a regional research network on multimorbid patients. BMC Med Res Methodol 23(1): 34. https://doi.org/10.1186/s12874-023-01855-2",
          "Thiese MS (2014) Observational and interventional study design types: an overview. Biochem Med (Zagreb) 24(2): 199\u2013210. https://doi.org/10.11613/BM.2014.022",
          "Vreman RA, Bloem LT, Van Oirschot S, Hoekman J, Van Der Elst ME, Leufkens HG, Klungel OH, Goettsch WG, Mantel-Teeuwisse AK (2022) The role of regulator-imposed post-approval studies in health technology assessments for conditionally approved drugs. Int J Health Policy Manag 11(5): 642\u2013650. https://doi.org/10.34172/ijhpm.2020.198",
          "Wang X, Kattan MW (2020) Cohort studies: design, analysis, and reporting. Chest 158(1): S72\u2013S78. https://doi.org/10.1016/j.chest.2020.03.014",
          "WHO (2024) Number of clinical trials by year, location, disease, phase, age and sex of trial participants. Global Observatory on Health R&D. https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development",
          "WHO (2025) Clinical trials and observational studies. World Health Organization. https://www.who.int/tools/antiretrovirals-in-pregnancy-research-toolkit/clinical-trials-and-observational-studies"
        ],
        "resource_type": {
          "title": "Journal article",
          "type": "publication",
          "subtype": "article"
        },
        "journal": {
          "issue": "",
          "pages": "1-6",
          "title": "Pharmacia",
          "volume": "72"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17472299"
              }
            }
          ]
        }
      },
      "title": "Non-interventional pharmacovigilance studies - an analysis of real-world data sources in the HMA-EMA catalogs",
      "links": {
        "self": "https://zenodo.org/api/records/17472300",
        "self_html": "https://zenodo.org/records/17472300",
        "preview_html": "https://zenodo.org/records/17472300?preview=1",
        "doi": "https://doi.org/10.3897/pharmacia.72.e170867",
        "self_doi": "https://doi.org/10.3897/pharmacia.72.e170867",
        "self_doi_html": "https://zenodo.org/doi/10.3897/pharmacia.72.e170867",
        "reserve_doi": "https://zenodo.org/api/records/17472300/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17472299",
        "parent_html": "https://zenodo.org/records/17472299",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17472300/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17472300/sequence/default",
        "files": "https://zenodo.org/api/records/17472300/files",
        "media_files": "https://zenodo.org/api/records/17472300/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17472300:PHAR_article_170867.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17472300:PHAR_article_170867.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17472300:PHAR_article_170867.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17472300:PHAR_article_170867.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17472300:PHAR_article_170867.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17472300:PHAR_article_170867.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17472300/files-archive",
        "archive_media": "https://zenodo.org/api/records/17472300/media-files-archive",
        "latest": "https://zenodo.org/api/records/17472300/versions/latest",
        "latest_html": "https://zenodo.org/records/17472300/latest",
        "versions": "https://zenodo.org/api/records/17472300/versions",
        "draft": "https://zenodo.org/api/records/17472300/draft",
        "access_links": "https://zenodo.org/api/records/17472300/access/links",
        "access_grants": "https://zenodo.org/api/records/17472300/access/grants",
        "access_users": "https://zenodo.org/api/records/17472300/access/users",
        "access_request": "https://zenodo.org/api/records/17472300/access/request",
        "access": "https://zenodo.org/api/records/17472300/access",
        "communities": "https://zenodo.org/api/records/17472300/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17472300/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17472300/request-deletion",
        "requests": "https://zenodo.org/api/records/17472300/requests"
      },
      "updated": "2025-10-29T08:31:44.226533+00:00",
      "recid": "17472300",
      "revision": 4,
      "files": [
        {
          "id": "b11efec6-16b4-4edd-be13-87ea1d57930c",
          "key": "PHAR_article_170867.pdf",
          "size": 305539,
          "checksum": "md5:18c4959782671caddd45c9158738bfd8",
          "links": {
            "self": "https://zenodo.org/api/records/17472300/files/PHAR_article_170867.pdf/content"
          }
        },
        {
          "id": "1a68cf77-2eeb-47d7-b23b-f5a6aa41bf80",
          "key": "PHAR_article_170867.xml",
          "size": 51694,
          "checksum": "md5:b008301c1555c37f80f21ac914945290",
          "links": {
            "self": "https://zenodo.org/api/records/17472300/files/PHAR_article_170867.xml/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "22270"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 0,
        "unique_downloads": 0,
        "views": 0,
        "unique_views": 0,
        "version_downloads": 0,
        "version_unique_downloads": 0,
        "version_unique_views": 0,
        "version_views": 0
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-28T07:35:47.881463+00:00",
      "modified": "2025-10-28T19:39:26.326828+00:00",
      "id": 17462383,
      "conceptrecid": "17462382",
      "doi": "10.5281/zenodo.17462383",
      "conceptdoi": "10.5281/zenodo.17462382",
      "doi_url": "https://doi.org/10.5281/zenodo.17462383",
      "metadata": {
        "title": "C12 \u2013 AuditLog.AI Global Compliance Matrix",
        "doi": "10.5281/zenodo.17462383",
        "publication_date": "2025-10-28",
        "description": "<div>\n<div>C12 &ndash; AuditLog.AI Global Compliance Matrix provides the harmonized cross-reference between AuditLog.AI&rsquo;s live runtime execution evidence and the governing clauses of FDA 21 CFR Part 11, EMA Annex 11, TGA / PIC/S PE 009-17, and international auditing standards (PCAOB AS 1105 / 1215 and ISA 230 / 500 / 240 Revised 2025). The matrix demonstrates that a single zero-custody, cryptographically anchored audit system can satisfy global validation, security, and documentation obligations across both regulatory and financial-assurance domains. All mapped evidence originates from the AuditLog.AI Runtime Execution and System Validation Evidence Dossier (DOI: [10.13140/RG.2.2.28551.25765] Zenodo: [10.5281/zenodo.17460850]), verified through UTC-synchronized timestamps, dual-hash proofs (SHA-256 + RIPEMD-160), OpenTimestamps attestation, and Bitcoin mainnet anchoring via OP_RETURN. Each clause is traceable to specific evidence items and session logs, ensuring reproducibility, human verification, and public auditability. The document establishes AuditLog.AI v4.0 as the first globally harmonized digital audit-trail system providing unified compliance alignment across FDA, EMA, TGA, PCAOB, and ISA standards. Ripemd160: fb1822a8113a1b691a7ef64bb7cd64ea2fa02bc8 Sha256: bbedad71af2064fb2456c73483984c538c66c2ed344f2a1cf34eef23cab14b81 Immutable Anchor: ORDINAL12|fb1822a8113a1b691a7ef64bb7cd64ea2fa02bc8|bbedad71 OP return: `e3dd84f739d2daf3f60177ce93e44648e9c57ef596090ef9a0474e0fc4fae326` ORDINAL: `7917e0f12fcff508d387733fd543451846316a21b16ca3f0d872b9849f94a904`</div>\n</div>",
        "access_right": "open",
        "creators": [
          {
            "name": "Telles, Fernando",
            "affiliation": "Cardiovascular Diagnostic Audit & AI Pty Ltd (CDA AI) ABN 19 638 019 431 | ACN 638 019 431",
            "orcid": "0000-0003-2379-2875"
          }
        ],
        "contributors": [
          {
            "name": "Yang, Jacob",
            "affiliation": "Cardiovascular Diagnostic Audit & AI Pty Ltd (CDA AI) ABN 19 638 019 431 | ACN 638 019 431",
            "type": "Other"
          },
          {
            "name": "Hookey, Benjamin",
            "affiliation": "Cardiovascular Diagnostic Audit & AI Pty Ltd (CDA AI) ABN 19 638 019 431 | ACN 638 019 431",
            "type": "Other"
          }
        ],
        "related_identifiers": [
          {
            "identifier": "10.5281/ZENODO.17460850",
            "relation": "isDocumentedBy",
            "resource_type": "publication-softwaredocumentation",
            "scheme": "doi"
          }
        ],
        "resource_type": {
          "title": "Software documentation",
          "type": "publication",
          "subtype": "softwaredocumentation"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17462382"
              }
            }
          ]
        }
      },
      "title": "C12 \u2013 AuditLog.AI Global Compliance Matrix",
      "links": {
        "self": "https://zenodo.org/api/records/17462383",
        "self_html": "https://zenodo.org/records/17462383",
        "preview_html": "https://zenodo.org/records/17462383?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17462383",
        "self_doi": "https://doi.org/10.5281/zenodo.17462383",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17462383",
        "reserve_doi": "https://zenodo.org/api/records/17462383/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17462382",
        "parent_html": "https://zenodo.org/records/17462382",
        "parent_doi": "https://doi.org/10.5281/zenodo.17462382",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17462382",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17462383/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17462383/sequence/default",
        "files": "https://zenodo.org/api/records/17462383/files",
        "media_files": "https://zenodo.org/api/records/17462383/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17462383:C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17462383:C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17462383:C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17462383:C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17462383:C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17462383:C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17462383/files-archive",
        "archive_media": "https://zenodo.org/api/records/17462383/media-files-archive",
        "latest": "https://zenodo.org/api/records/17462383/versions/latest",
        "latest_html": "https://zenodo.org/records/17462383/latest",
        "versions": "https://zenodo.org/api/records/17462383/versions",
        "draft": "https://zenodo.org/api/records/17462383/draft",
        "access_links": "https://zenodo.org/api/records/17462383/access/links",
        "access_grants": "https://zenodo.org/api/records/17462383/access/grants",
        "access_users": "https://zenodo.org/api/records/17462383/access/users",
        "access_request": "https://zenodo.org/api/records/17462383/access/request",
        "access": "https://zenodo.org/api/records/17462383/access",
        "communities": "https://zenodo.org/api/records/17462383/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17462383/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17462383/request-deletion",
        "requests": "https://zenodo.org/api/records/17462383/requests"
      },
      "updated": "2025-10-28T19:39:26.326828+00:00",
      "recid": "17462383",
      "revision": 6,
      "files": [
        {
          "id": "b52051f5-3320-4cd7-b2a9-82792db92195",
          "key": "C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf",
          "size": 1208116,
          "checksum": "md5:99b7e9e8a65fe97521f3c25533d14cd4",
          "links": {
            "self": "https://zenodo.org/api/records/17462383/files/C12_AuditLog.AI_Globally_Harmonized_Cryptographically_Anchored_Compliance_Map_for_Digital_Audit_and_Reproducibility_Systems_FINAL_METADATA___20251028T043727Z.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "1357001"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 12,
        "unique_downloads": 5,
        "views": 9,
        "unique_views": 6,
        "version_downloads": 12,
        "version_unique_downloads": 5,
        "version_unique_views": 6,
        "version_views": 9
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-28T02:56:26.795131+00:00",
      "modified": "2025-10-28T02:56:27.184532+00:00",
      "id": 17460850,
      "conceptrecid": "17460849",
      "doi": "10.5281/zenodo.17460850",
      "conceptdoi": "10.5281/zenodo.17460849",
      "doi_url": "https://doi.org/10.5281/zenodo.17460850",
      "metadata": {
        "title": "AuditLog.AI \u2014 Runtime Execution and System Validation Evidence Dossier | End\u2011to\u2011End Operational Proof During Regulatory Global Submission",
        "doi": "10.5281/zenodo.17460850",
        "publication_date": "2025-10-27",
        "description": "<div>\n<div>This document forms part of the AuditLog.AI Global Regulatory Submission Package (v4.0) &mdash; providing immutable, reproducible proof of execution for validation, compliance, and quality-assurance evidence across FDA, EMA, TGA, PCAOB, and ISA frameworks.</div>\n<div>AuditLog.AI operates under the Sentinel Quality Management System (QMS) using a zero-custody model, ensuring that no raw data or identifiers ever leave the user&rsquo;s environment.</div>\n<div>Each audit event is cryptographically sealed (SHA-256 &rarr; RIPEMD-160), time-stamped through OpenTimestamps, and permanently anchored to the Bitcoin mainnet via OP_RETURN.</div>\n<div>These anchors establish verifiable, regulator-grade proof of integrity, authenticity, and human-verified control.</div>\n<div>Public verification of this artifact may be performed through any independent blockchain explorer using the transaction IDs and digests provided below.</div>\n<div>This open-submission release aligns with the principles of transparency and reproducibility for digital audit systems, supporting global harmonization between Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and International Standards on Auditing (ISA).</div>\n<div>It may be freely referenced in regulatory, clinical, or assurance contexts under citation of its dual DOI and associated Bitcoin anchors.</div>\n<br>\n<div>- File Reference: `AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf`</div>\n<div>- SHA-256: `fc46851b4854ca45798b741c0fb001eaa0945eb73c98795900c87939acb30d8a`</div>\n<div>- RIPEMD-160: `b0c8b2223eab705cac6bf7801b64945f7ed47022`</div>\n<div>- OTS File: `AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf.hash.ots`</div>\n<div>- OP_RETURN Anchor: `ORDINAL11|b0c8b2223eab705cac6bf7801b64945f7ed47022|fc46851b` | Transaction ID: `a09523a5e311d5e5213cba7cc39ec3a274aa1cc017be369cfa5786c3677a1540` | Block: `921107`</div>\n<div>- Ordinal Anchor: `ORDINAL11|b0c8b2223eab705cac6bf7801b64945f7ed47022|fc46851b` | Transaction ID: `6754818e57d5dcc16a7fccdb1d36bb213cd39ae4a180e17923387738f38a3f41` | Block: `921109`</div>\n<br>\n<div>- Anchoring Session log: `session_log_AuditLogAI.REG.GlobalSubmission.v4059_20251027T231229.358107Z.json`</div>\n<div>- SHA-256: `db4451a879e62a1e34a14a6052a442172be6c8798aff163a9564a31beb768d21`</div>\n<div>- RIPEMD-160: `d51e9af05a7b8f32db2f85ab0a76ea7e71cadede`</div>\n<div>- Session OTS File: `session_log_AuditLogAI.REG.GlobalSubmission.v4059_20251027T231229.358107Z.hash.ots`</div>\n<div>- Session OP_RETURN Anchor: `SENTINEL|SESSION|d51e9af05a7b8f32db2f85ab0a76ea7e71cadede|db4451a8`</div>\n<div>- Transaction ID: `06028cfbf809665838e437dcad6d01c48d5c4679ebdbe045ea12ed4c311c020e`</div>\n<div>- Date of Existence (UTC): `2025-10-27T23:14:36Z` (TXID broadcast time confirming file existence as of Bitcoin block 921094.)</div>\n</div>",
        "access_right": "open",
        "creators": [
          {
            "name": "Telles, Fernando",
            "affiliation": "Cardiovascular Diagnostic Audit & AI Pty Ltd (CDA AI) ABN 19 638 019 431 | ACN 638 019 431",
            "orcid": "0000-0003-2379-2875"
          }
        ],
        "contributors": [
          {
            "name": "Yang, Jacob",
            "affiliation": "Cardiovascular Diagnostic Audit & AI Pty Ltd (CDA AI) ABN 19 638 019 431 | ACN 638 019 431",
            "type": "Other"
          },
          {
            "name": "Hookey, Benjamin",
            "affiliation": "Cardiovascular Diagnostic Audit & AI Pty Ltd (CDA AI) ABN 19 638 019 431 | ACN 638 019 431",
            "type": "Other"
          }
        ],
        "references": [
          "Telles, Fernando. *Sentinel Protocol v3.1 \u2013 Infrastructure Reproducibility and Public Verification Log.* CDA AI Pty Ltd, July 2025.   DOI: [10.13140/RG.2.2.29180.65924](http://dx.doi.org/10.13140/RG.2.2.29180.65924)   Zenodo: [10.5281/zenodo.16607606](https://doi.org/10.5281/zenodo.16607606)",
          "Telles, Fernando. *Ordinal 06 \u2013 Immutable Verification of Infrastructure Audit Log (Ordinal 05) under Sentinel Protocol v3.1.* CDA AI Pty Ltd, July 2025.   DOI: [10.13140/RG.2.2.21019.78882](http://dx.doi.org/10.13140/RG.2.2.21019.78882)   Zenodo: [10.5281/zenodo.16777715](https://doi.org/10.5281/zenodo.16777715)"
        ],
        "resource_type": {
          "title": "Software documentation",
          "type": "publication",
          "subtype": "softwaredocumentation"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17460849"
              }
            }
          ]
        }
      },
      "title": "AuditLog.AI \u2014 Runtime Execution and System Validation Evidence Dossier | End\u2011to\u2011End Operational Proof During Regulatory Global Submission",
      "links": {
        "self": "https://zenodo.org/api/records/17460850",
        "self_html": "https://zenodo.org/records/17460850",
        "preview_html": "https://zenodo.org/records/17460850?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17460850",
        "self_doi": "https://doi.org/10.5281/zenodo.17460850",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17460850",
        "reserve_doi": "https://zenodo.org/api/records/17460850/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17460849",
        "parent_html": "https://zenodo.org/records/17460849",
        "parent_doi": "https://doi.org/10.5281/zenodo.17460849",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17460849",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17460850/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17460850/sequence/default",
        "files": "https://zenodo.org/api/records/17460850/files",
        "media_files": "https://zenodo.org/api/records/17460850/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17460850:AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17460850:AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17460850:AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17460850:AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17460850:AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17460850:AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17460850/files-archive",
        "archive_media": "https://zenodo.org/api/records/17460850/media-files-archive",
        "latest": "https://zenodo.org/api/records/17460850/versions/latest",
        "latest_html": "https://zenodo.org/records/17460850/latest",
        "versions": "https://zenodo.org/api/records/17460850/versions",
        "draft": "https://zenodo.org/api/records/17460850/draft",
        "access_links": "https://zenodo.org/api/records/17460850/access/links",
        "access_grants": "https://zenodo.org/api/records/17460850/access/grants",
        "access_users": "https://zenodo.org/api/records/17460850/access/users",
        "access_request": "https://zenodo.org/api/records/17460850/access/request",
        "access": "https://zenodo.org/api/records/17460850/access",
        "communities": "https://zenodo.org/api/records/17460850/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17460850/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17460850/request-deletion",
        "requests": "https://zenodo.org/api/records/17460850/requests"
      },
      "updated": "2025-10-28T02:56:27.184532+00:00",
      "recid": "17460850",
      "revision": 3,
      "files": [
        {
          "id": "e52e3fb7-edca-4992-af91-85842cc0a2f6",
          "key": "AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf",
          "size": 23469649,
          "checksum": "md5:cc02813b54797bff226f202cb5ea6be5",
          "links": {
            "self": "https://zenodo.org/api/records/17460850/files/AuditLog.AI_Runtime_Execution_and_System_Validation_Evidence_Dossier_FINAL_METADATA___20251027T231047Z.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "1357001"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 39,
        "unique_downloads": 4,
        "views": 16,
        "unique_views": 12,
        "version_downloads": 39,
        "version_unique_downloads": 4,
        "version_unique_views": 12,
        "version_views": 16
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-27T04:20:53.070190+00:00",
      "modified": "2025-10-27T04:20:53.609609+00:00",
      "id": 17451709,
      "conceptrecid": "17451708",
      "doi": "10.5281/zenodo.17451709",
      "conceptdoi": "10.5281/zenodo.17451708",
      "doi_url": "https://doi.org/10.5281/zenodo.17451709",
      "metadata": {
        "title": "End-to-End Oncology Clinical Trial LLM Efficiency For Industry Adoption with FDA/ICH Regulations",
        "doi": "10.5281/zenodo.17451709",
        "publication_date": "2025-10-27",
        "description": "<p>The process of a new oncology treatment from drug discovery and preclinical studies through Phase III clinical trials and FDA review can take over a decade and cost hundreds of millions of dollars. Therefore, automated and easy to use large language models which have adapted to code generation for production use of sensitive data should be implemented into cancer trial workflows at scale. Here, LLMs were implemented throughout the study to create table templates, datasets based on author and online literature; and followed by triple and quintuple LLM workflows for optimization, table population, peer review, and meta-analyses. Primary models utilized were Sonnet 4.5 Extended, Gemini 2.5 Pro, GPT-5 High, and Grok 4 Fast - with Sonnet being used the most to quickly solve increasingly larger problems and reach consensuses between other LLM responses. The iterated workflow features 12 tables from discovery through Phase III trials, NDA/BOA &amp; FDA Review that identified potential prior LLM applications, with estimated LLM time and cost reductions for trial activities. These itemized values for each table were summed by AI and provided in a cost summary of an entire glioblastoma drug development process. The 2025 trial baseline total was estimated to be 10-15 years at a cost of \\$282M-\\$837M, while the LLM/AI assisted workflow was projected to be 4.8-7.7 years at \\$215M-\\$673M, which is 52-73% faster and 24-50% less expensive. Key performance indicators of baseline vs. LLM, acceleration and cost reduction areas, regulatory framework summary, and call to action were also provided by Sonnet, marking a transition to broader adoption of LLMs for oncology clinical trials. Note: LLM outputs and LLM-generated code locally executed with patient data may require FDA approval.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Kawchak, Kevin",
            "affiliation": "ChemicalQDevice",
            "orcid": "0009-0007-5457-8667"
          }
        ],
        "keywords": [
          "Oncology",
          "Drug Discovery",
          "Preclinical",
          "Phase III Trial",
          "FDA",
          "LLM"
        ],
        "dates": [
          {
            "type": "created"
          }
        ],
        "language": "eng",
        "resource_type": {
          "title": "Preprint",
          "type": "publication",
          "subtype": "preprint"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17451708"
              }
            }
          ]
        }
      },
      "title": "End-to-End Oncology Clinical Trial LLM Efficiency For Industry Adoption with FDA/ICH Regulations",
      "links": {
        "self": "https://zenodo.org/api/records/17451709",
        "self_html": "https://zenodo.org/records/17451709",
        "preview_html": "https://zenodo.org/records/17451709?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17451709",
        "self_doi": "https://doi.org/10.5281/zenodo.17451709",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17451709",
        "reserve_doi": "https://zenodo.org/api/records/17451709/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17451708",
        "parent_html": "https://zenodo.org/records/17451708",
        "parent_doi": "https://doi.org/10.5281/zenodo.17451708",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17451708",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17451709/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17451709/sequence/default",
        "files": "https://zenodo.org/api/records/17451709/files",
        "media_files": "https://zenodo.org/api/records/17451709/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17451709:End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17451709:End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17451709:End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17451709:End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17451709:End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17451709:End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17451709/files-archive",
        "archive_media": "https://zenodo.org/api/records/17451709/media-files-archive",
        "latest": "https://zenodo.org/api/records/17451709/versions/latest",
        "latest_html": "https://zenodo.org/records/17451709/latest",
        "versions": "https://zenodo.org/api/records/17451709/versions",
        "draft": "https://zenodo.org/api/records/17451709/draft",
        "access_links": "https://zenodo.org/api/records/17451709/access/links",
        "access_grants": "https://zenodo.org/api/records/17451709/access/grants",
        "access_users": "https://zenodo.org/api/records/17451709/access/users",
        "access_request": "https://zenodo.org/api/records/17451709/access/request",
        "access": "https://zenodo.org/api/records/17451709/access",
        "communities": "https://zenodo.org/api/records/17451709/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17451709/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17451709/request-deletion",
        "requests": "https://zenodo.org/api/records/17451709/requests"
      },
      "updated": "2025-10-27T04:20:53.609609+00:00",
      "recid": "17451709",
      "revision": 4,
      "files": [
        {
          "id": "1cad2cd4-747d-43d2-8e4e-f969e291e42e",
          "key": "Prompt_A_Table_Templates.zip",
          "size": 1097050,
          "checksum": "md5:c57be8b2ce4ab9d516ed34cf8ceb2955",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_A_Table_Templates.zip/content"
          }
        },
        {
          "id": "e64ac61e-28ca-4afb-bb19-7c5a38065f0a",
          "key": "Prompt_J_Baseline_Workflow_Population.zip",
          "size": 2361285,
          "checksum": "md5:a84713e55eae9ed715bf54cfd71d0ac2",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_J_Baseline_Workflow_Population.zip/content"
          }
        },
        {
          "id": "88030f88-8c53-4833-8e09-5d21169574dd",
          "key": "Prompt_I_Comprehensive_Tables_Consensus.zip",
          "size": 4217964,
          "checksum": "md5:06cf50748465743b4996251a9498acca",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_I_Comprehensive_Tables_Consensus.zip/content"
          }
        },
        {
          "id": "89d204b1-f478-4971-a229-fedddcd6f8a4",
          "key": "Prompt_E_Online_Tables_Population.zip",
          "size": 1323531,
          "checksum": "md5:1a443305b5627bad80aa35273106eaef",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_E_Online_Tables_Population.zip/content"
          }
        },
        {
          "id": "10dcf6a4-7588-4dcf-a777-dfd9d20f365b",
          "key": "Prompt_B_Table_Optimization.zip",
          "size": 2623185,
          "checksum": "md5:65ed3324c730e3f827f2268e39609f51",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_B_Table_Optimization.zip/content"
          }
        },
        {
          "id": "8a327d0b-a941-4a74-8748-ca2d8035344c",
          "key": "Prompt_F_LaTeX_Table_Conversions.zip",
          "size": 1491256,
          "checksum": "md5:11e21dc8cc1b59ea535fb75d3bda4e76",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_F_LaTeX_Table_Conversions.zip/content"
          }
        },
        {
          "id": "949c998e-d48a-4b48-a0c0-25a00145b4b9",
          "key": "End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf",
          "size": 271622,
          "checksum": "md5:964ea77ce085460fcca32d6292e5ecc6",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/End_to_End_Oncology_Clinical_Trial_LLM_Efficiency_For_Industry_Adoption_with_FDA_ICH_Regulations.pdf/content"
          }
        },
        {
          "id": "2d456377-aacd-468d-8e2e-636e2c3270ab",
          "key": "Prompt_G_Online_Tables_Optimization.zip",
          "size": 1740206,
          "checksum": "md5:d76b24fb2bc431feb4125e6cc21d7a19",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_G_Online_Tables_Optimization.zip/content"
          }
        },
        {
          "id": "734edb9c-3eaf-4506-be51-8853c233c862",
          "key": "Prompt_H_Table_Optimizations.zip",
          "size": 2196955,
          "checksum": "md5:27a74fec54ac0c3c6ee8ce015d48fca5",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_H_Table_Optimizations.zip/content"
          }
        },
        {
          "id": "7e0c9733-a9f9-41ca-b0bb-0a9d6f233655",
          "key": "Prompt_C_14_Working_Tables.zip",
          "size": 1064474,
          "checksum": "md5:a82a77313ffe9525aa44448406ee1c28",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_C_14_Working_Tables.zip/content"
          }
        },
        {
          "id": "95cbe769-073a-457a-9b4b-8a45d435bc43",
          "key": "Prompt_D_Author_Tables_Population.zip",
          "size": 10087110,
          "checksum": "md5:033469eafb8bb234f8ce89cc8361645b",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_D_Author_Tables_Population.zip/content"
          }
        },
        {
          "id": "ae32a006-3e91-40ca-8f0a-c77a408de7de",
          "key": "Prompt_K_Alternative_Baseline_Workflow.zip",
          "size": 1001271,
          "checksum": "md5:209f437ef73a250d950365d334c9fa7b",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_K_Alternative_Baseline_Workflow.zip/content"
          }
        },
        {
          "id": "3b9cf5f0-0d08-4643-9fa9-0b38bed19566",
          "key": "Prompt_M_Meta_Prompts_for_Peer_Review_Analysis.zip",
          "size": 1091412,
          "checksum": "md5:4c79740b3e368328bd4694a708c25b3e",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_M_Meta_Prompts_for_Peer_Review_Analysis.zip/content"
          }
        },
        {
          "id": "078815dc-2ae7-44f7-9afc-931b04293df3",
          "key": "Prompt_N_Prompt_O_LLM_Meta_Analyses_of_Prompt_M.zip",
          "size": 1604488,
          "checksum": "md5:d93c5fc3218beddf594d7333a4c7f867",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_N_Prompt_O_LLM_Meta_Analyses_of_Prompt_M.zip/content"
          }
        },
        {
          "id": "d4df84ba-802c-472d-8940-5a1eebca03db",
          "key": "Zip_Main_Paper_Files.zip",
          "size": 57436,
          "checksum": "md5:a03c599f726bcbbdefaa63f17e76d341",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Zip_Main_Paper_Files.zip/content"
          }
        },
        {
          "id": "6a4a6af5-138e-4f75-ad21-421f42c55866",
          "key": "Prompt_L_Quintuple_LLM_Peer_Review.zip",
          "size": 27328554,
          "checksum": "md5:56765fd77c4e30833b2b41e0b14475c1",
          "links": {
            "self": "https://zenodo.org/api/records/17451709/files/Prompt_L_Quintuple_LLM_Peer_Review.zip/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "1171568"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 55,
        "unique_downloads": 41,
        "views": 85,
        "unique_views": 75,
        "version_downloads": 55,
        "version_unique_downloads": 41,
        "version_unique_views": 75,
        "version_views": 85
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-26T07:29:02.169759+00:00",
      "modified": "2025-10-26T07:29:02.407305+00:00",
      "id": 17446449,
      "conceptrecid": "17446448",
      "doi": "10.12692/jbes/27.2.1-9",
      "doi_url": "https://doi.org/10.12692/jbes/27.2.1-9",
      "metadata": {
        "title": "Bacteriological analysis of selected fishes sold in wet markets in Tuguegarao city, Cagayan, Philippines",
        "doi": "10.12692/jbes/27.2.1-9",
        "publication_date": "2025-08-06",
        "description": "<p>Fish and fish products are familiar sources of foodborne outbreaks and recalls. Pathogenic and spoilage bacteria can enter any production, processing, or distribution stage, threatening consumer safety. Fish locally sold at Tuguegarao City, Cagayan, Philippines wet market, namely&nbsp;<em>Oreochromis niloticus</em>&nbsp;(tilapia),&nbsp;<em>Chanos chanos</em>&nbsp;(bangus),&nbsp;<em>Siluriformes</em>&nbsp;(hito), and&nbsp;<em>Decapterus macarellus</em>&nbsp;(galunggong), were collected and sent to the Department of Agriculture Cagayan Valley Integrated Laboratory (DA-CVIAL) Regional Feed Chemical Analysis Laboratory (RFCAL) for bacteriological analysis. Total bacterial count, total coliform/<em>E. coli</em>&nbsp;count,&nbsp;<em>S. aureus</em>&nbsp;count, and presence of Salmonella spp. were conducted for analysis. Two tilapia and one hito sample exceeded the threshold for safety standards on the total bacterial count. Aside from these, all fish species have unacceptable levels of&nbsp;<em>E. coli</em>&nbsp;except for galunggong and tilapia (not tested for&nbsp;<em>E. coli</em>). Analysis of&nbsp;<em>Salmonella</em>&nbsp;yielded concerning results. Only two hito samples and three tilapia samples tested negative for the microorganism. This suggests the presence of Salmonella in a significant portion of the fish across all species.&nbsp;<em>S. aureus</em> contamination was not detected in any of the fish samples. By the FDA standards (Circular No. 2022-012), no species passed the microbiological tests. High levels of fish contamination may be caused by various factors, including environmental temperature, which can allow certain organisms to thrive, poor personal hygiene of the fish handler, and contaminated water sources that may contain fecal matter.</p>\n<p>published by the <a href=\"https://innspub.net/journal-of-biodiversity-and-environmental-sciences/\"><strong>Journal of Biodiversity and Environmental Sciences | JBES</strong></a></p>\n<div>\n<div>&nbsp;</div>\n</div>",
        "access_right": "open",
        "creators": [
          {
            "name": "Jay Andrea Vea D., Israel",
            "affiliation": "Department of Medical Laboratory Science, College of Allied Health Sciences, Cagayan State University, Andrews Campus, Caritan, Tuguegarao City, Cagayan, Philippines"
          }
        ],
        "contributors": [
          {
            "name": "Lara Melissa, G. Luis",
            "affiliation": "Department of Medical Laboratory Science, College of Allied Health Sciences, Cagayan State University, Andrews Campus, Caritan, Tuguegarao City, Cagayan, Philippines",
            "type": "Researcher"
          },
          {
            "name": "Dorina D., Sabatin",
            "affiliation": "Department of Medical Laboratory Science, College of Allied Health Sciences, Cagayan State University, Andrews Campus, Caritan, Tuguegarao City, Cagayan, Philippines",
            "type": "Researcher"
          },
          {
            "name": "Gina M., Zamora",
            "affiliation": "Department of Medical Laboratory Science, College of Allied Health Sciences, Cagayan State University, Andrews Campus, Caritan, Tuguegarao City, Cagayan, Philippines",
            "type": "Researcher"
          },
          {
            "name": "Julius T., Capili",
            "affiliation": "Department of Medical Laboratory Science, College of Allied Health Sciences, Cagayan State University, Andrews Campus, Caritan, Tuguegarao City, Cagayan, Philippines",
            "type": "Researcher"
          }
        ],
        "keywords": [
          "Bacteriological analysis",
          "Fishes",
          "Wet market"
        ],
        "dates": [
          {
            "type": "available",
            "description": "article published"
          }
        ],
        "references": [
          "Abdelaziz Hassan A, Abdel Aziem Abo Zaid F, Atef HA, El Shafei M, Mansour K, Snosy A, Abo-zaid KF. 2016. Effect of microbiological contamination and pollution of water on the health status of fish. Animal Health Research Institute (AHRI) 3(5), 178\u2013192.",
          "Alikunhi NM, Batang ZB, AlJahdali HA, Aziz MAM, Al-Suwailem AM. 2017. Culture-dependent bacteria in commercial fishes: Qualitative assessment and molecular identification using 16S rRNA gene sequencing. Saudi Journal of Biological Sciences 24(6), 1105\u20131116. https://doi.org/10.1016/j.sjbs.2016.05.017",
          "Beyari EA, Aly MM, Jastaniah SD. 2021. Incidence of foodborne bacteria that cause serious health hazards in fish: A review.",
          "Bibi F, Ahmad AN, Akhtar M. 2015. Occurrence of Salmonella in freshwater fishes: A review. Journal of Animal and Plant Sciences. https://www.researchgate.net/publication/282356746",
          "Brauge T, Mougin J, Ells T, Midelet G. 2024. Sources and contamination routes of seafood with human pathogenic Vibrio spp.: A farm\u2010to\u2010fork approach. Comprehensive Reviews in Food Science and Food Safety 23(1). https://doi.org/10.1111/1541-4337.13283",
          "Budiati T, Rusul G, Wan-Abdullah WN, Arip YM, Ahmad R, Thong KL. 2013. Prevalence, antibiotic resistance and plasmid profiling of Salmonella in catfish (Clarias gariepinus) and tilapia (Tilapia mossambica) obtained from wet markets and ponds in Malaysia. Aquaculture 372-375, 127-132. https://doi.org/10.1016/j.aquaculture.2012.11.003",
          "Cabral JPS. 2010. Water microbiology: Bacterial pathogens and water. International Journal of Environmental Research and Public Health 7(10), 3657-3703. https://doi.org/10.3390/ijerph7103657",
          "Dissasa G, Lemma B, Mamo H. 2022. Isolation and identification of major bacteria from three Ethiopian rift valley lakes live and processed fish, and water samples: Implications in sanitary system of fish products. BMC Veterinary Research 18(1), 439. https://doi.org/10.1186/s12917-022-03508-w",
          "Elgendy MY, Ali SE, Abbas WT, Algammal AM, Abdelsalam M. 2023. The role of marine pollution on the emergence of fish bacterial diseases. Chemosphere 344, 140366. https://doi.org/10.1016/j.chemosphere.2023.140366",
          "Fernandes R. 2009. Microbiology handbook: Fish and seafood. 2nd edition. Leatherhead Publishing and the Royal Society of Chemistry.",
          "Gauthier DT. 2015. Bacterial zoonoses of fishes: A review and appraisal of evidence for linkages between fish and human infections. Veterinary Journal 203(1), 27-35. https://doi.org/10.1016/j.tvjl.2014.10.028",
          "Giddings CD, Ansari AA, Silva PDa. 2015. Microbiological quality of three freshwater fish species from two local markets in Region 6, (Corentyne, East Berbice) Guyana. Asia Journal of Applied Microbiology 2(4), 35\u201343. https://doi.org/10.18488/journal.33/2015.2.4/33.4.35.43",
          "Han F, Huang X, Mahunu GK. 2017. Exploratory review on safety of edible raw fish per the hazard factors and their detection methods. Trends in Food Science & Technology 59, 37\u201348. https://doi.org/10.1016/j.tifs.2016.11.004",
          "Karanth S, Feng S, Patra D, Pradhan AK. 2023. Linking microbial contamination to food spoilage and food waste: The role of smart packaging, spoilage risk assessments, and date labeling. Frontiers in Microbiology 14, 1198124. https://doi.org/10.3389/fmicb.2023.1198124",
          "Manyi-Loh CE, Lues R. 2025. Listeria monocytogenes and listeriosis: The global enigma. Foods 14(7), 1266. https://doi.org/10.3390/foods14071266",
          "Marchello CS, Fiorino F, Pettini E, Crump JA, Martin LB, Breghi G, Canals R, Gordon MA, Hanumunthadu B, Jacobs J, Kariuki S, Kim JH, Malvolti S, Mantel C, Marks F, Medaglini D, Mogasale V, Muthumbi E, Onsare R, Tack B. 2021. Incidence of non-typhoidal Salmonella invasive disease: A systematic review and meta-analysis. Journal of Infection 83(5), 523\u2013532. https://doi.org/10.1016/j.jinf.2021.06.029",
          "Mladenovi\u0107 KG, Grujovi\u0107 M\u017d, Ki\u0161 M, Furmeg S, Tkalec VJ, Stefanovi\u0107 OD, Koci\u0107-Tanackov SD. 2021. Enterobacteriaceae in food safety with an emphasis on raw milk and meat. Applied Microbiology and Biotechnology 105(23), 8615\u20138627. https://doi.org/10.1007/s00253-021-11655-7",
          "Ndraha N, Lin H, Hsiao H, Lin H. 2024. Managing the microbiological safety of tilapia from farm to consumer. Comprehensive Reviews in Food Science and Food Safety 23(5), 70023. https://doi.org/10.1111/1541-4337.70023",
          "Novotny L, Dvorska L, Lorencova A, Beran V, Pavlik I. 2004. Fish: A potential source of bacterial pathogens for human beings. Veterin\u00e1rn\u00ed Medic\u00edna 49(9), 343\u2013358. https://doi.org/10.17221/5715-VETMED",
          "Popa GL, Popa MI. 2021. Salmonella spp. Infection- A continuous threat worldwide. GERMS 11(1), 88-96. https://doi.org/10.18683/germs.2021.1244",
          "Republic of the Philippines. 2013. Republic Act No. 10611: An act to strengthen the Philippine food safety regulatory system to protect consumer health and facilitate market access of local foods and food products, and for other purposes. Supreme Court E-Library. https://elibrary.judiciary.gov.ph/thebookshelf/showdocs/2/58856",
          "Roy PK, Roy A, Jeon EB, DeWitt CAM, Park JW, Park SY. 2024. Comprehensive analysis of predominant pathogenic bacteria and viruses in seafood products. Comprehensive Reviews in Food Science and Food Safety 23(4), 13410. https://doi.org/10.1111/1541-4337.13410",
          "Shafik H, El-Dosoky H. 2017. Bacteriological safety of fresh fish from urban and rural areas sold at Mansoura city. Assiut Veterinary Medical Journal 63(153), 19\u201325. https://doi.org/10.21608/avmj.2017.185341",
          "Sheng L, Wang L. 2021. The microbial safety of fish and fish products: Recent advances in understanding its significance, contamination sources, and control strategies. Comprehensive Reviews in Food Science and Food Safety 20(1), 738-786. https://doi.org/10.1111/1541-4337.12671",
          "Svobodov\u00e1 Z. 1993. Water quality and fish health. Food and Agriculture Organization of the United Nations.",
          "Tan SL, Lee HY, Mahyudin NA. 2014. Antimicrobial resistance of Escherichia coli and Staphylococcus aureus isolated from food handler's hands. Food Control 44, 203-207. https://doi.org/10.1016/j.foodcont.2014.04.008",
          "Terentjeva M, Eizenberga I, Novoslavskij A, Strazdi\u0146a V, Valci\u0146a O, O\u0161mjana J, B\u0113rzi\u0146\u0161 A. 2015. Bacterial microflora of freshwater fish originated from Usmas Lake in Latvia. Journal of Microbiology, Biotechnology and Food Sciences 4(Special issue 1- Microbiology), 74-77. https://doi.org/10.15414/jmbfs.2015.4.ispecial1.74-77"
        ],
        "language": "eng",
        "resource_type": {
          "title": "Journal article",
          "type": "publication",
          "subtype": "article"
        },
        "journal": {
          "issue": "2",
          "pages": ". 1-9",
          "title": "Journal of Biodiversity and Environmental Sciences (JBES)",
          "volume": "27"
        },
        "alternate_identifiers": [
          {
            "identifier": "https://innspub.net/bacteriological-analysis-of-selected-fishes-sold-in-wet-markets-in-tuguegarao-city-cagayan-philippines/"
          }
        ],
        "license": {
          "id": "cc-by-4.0"
        },
        "communities": [
          {
            "id": "jbes"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17446448"
              }
            }
          ]
        }
      },
      "title": "Bacteriological analysis of selected fishes sold in wet markets in Tuguegarao city, Cagayan, Philippines",
      "links": {
        "self": "https://zenodo.org/api/records/17446449",
        "self_html": "https://zenodo.org/records/17446449",
        "preview_html": "https://zenodo.org/records/17446449?preview=1",
        "doi": "https://doi.org/10.12692/jbes/27.2.1-9",
        "self_doi": "https://doi.org/10.12692/jbes/27.2.1-9",
        "self_doi_html": "https://zenodo.org/doi/10.12692/jbes/27.2.1-9",
        "reserve_doi": "https://zenodo.org/api/records/17446449/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17446448",
        "parent_html": "https://zenodo.org/records/17446448",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17446449/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17446449/sequence/default",
        "files": "https://zenodo.org/api/records/17446449/files",
        "media_files": "https://zenodo.org/api/records/17446449/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17446449:JBES-V27-No2-p1-9.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17446449:JBES-V27-No2-p1-9.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17446449:JBES-V27-No2-p1-9.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17446449:JBES-V27-No2-p1-9.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17446449:JBES-V27-No2-p1-9.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17446449:JBES-V27-No2-p1-9.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17446449/files-archive",
        "archive_media": "https://zenodo.org/api/records/17446449/media-files-archive",
        "latest": "https://zenodo.org/api/records/17446449/versions/latest",
        "latest_html": "https://zenodo.org/records/17446449/latest",
        "versions": "https://zenodo.org/api/records/17446449/versions",
        "draft": "https://zenodo.org/api/records/17446449/draft",
        "access_links": "https://zenodo.org/api/records/17446449/access/links",
        "access_grants": "https://zenodo.org/api/records/17446449/access/grants",
        "access_users": "https://zenodo.org/api/records/17446449/access/users",
        "access_request": "https://zenodo.org/api/records/17446449/access/request",
        "access": "https://zenodo.org/api/records/17446449/access",
        "communities": "https://zenodo.org/api/records/17446449/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17446449/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17446449/request-deletion",
        "requests": "https://zenodo.org/api/records/17446449/requests"
      },
      "updated": "2025-10-26T07:29:02.407305+00:00",
      "recid": "17446449",
      "revision": 4,
      "files": [
        {
          "id": "d97cf647-cf22-4210-8723-060cc4127251",
          "key": "JBES-V27-No2-p1-9.pdf",
          "size": 982052,
          "checksum": "md5:30b4613319a42c69d636ee573bef761d",
          "links": {
            "self": "https://zenodo.org/api/records/17446449/files/JBES-V27-No2-p1-9.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "598309"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 4,
        "unique_downloads": 2,
        "views": 10,
        "unique_views": 9,
        "version_downloads": 4,
        "version_unique_downloads": 2,
        "version_unique_views": 9,
        "version_views": 10
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-25T20:11:20.874664+00:00",
      "modified": "2025-10-25T20:11:21.209863+00:00",
      "id": 15324142,
      "conceptrecid": "15324141",
      "doi": "10.5281/zenodo.15324142",
      "conceptdoi": "10.5281/zenodo.15324141",
      "doi_url": "https://doi.org/10.5281/zenodo.15324142",
      "metadata": {
        "title": "Enzyme-Linked Immuno-Sorbent Assay (ELISA) Technique for Mycotoxins",
        "doi": "10.5281/zenodo.15324142",
        "publication_date": "2023-07-03",
        "description": "<p>This presentation is part of the training material from FunShield4Med 1st Summer School entitled \"Mycotoxins under Climate Change\" held at University of Parma on 3-7 July 2023. This session introduces ELISA, a widely used lab technique for detecting and quantifying proteins, antibodies, and toxins&mdash;such as aflatoxins in food. It explains the step-by-step principle behind ELISA, including coating, binding, washing, detection, and signal measurement. The presentation details four main formats (direct, indirect, sandwich, and competitive ELISA) and focuses on the Veratox&reg; ELISA method, a validated, cost-effective tool for quantifying aflatoxins in grains. It also outlines U.S. FDA regulatory limits and provides practical guidance on sample preparation, assay setup, and result interpretation.&nbsp;</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Proestos, Charalampos",
            "affiliation": "National and Kapodistrian University of Athens",
            "orcid": "0000-0002-3450-5969"
          }
        ],
        "resource_type": {
          "title": "Presentation",
          "type": "presentation"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "grants": [
          {
            "code": "101079173",
            "internal_id": "10.13039/501100000780::101079173",
            "funder": {
              "name": "European Commission",
              "doi": "10.13039/501100000780",
              "acronym": "EC"
            },
            "title": "Shielding food safety and security by enabling the foresight of fungal spoilage and mycotoxins threats in the Mediterranean region under climate change conditions",
            "acronym": "FunShield4Med",
            "program": "HORIZON.4.1",
            "url": "https://cordis.europa.eu/projects/101079173"
          }
        ],
        "communities": [
          {
            "id": "eu"
          },
          {
            "id": "funshield4med"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "15324141"
              }
            }
          ]
        }
      },
      "title": "Enzyme-Linked Immuno-Sorbent Assay (ELISA) Technique for Mycotoxins",
      "links": {
        "self": "https://zenodo.org/api/records/15324142",
        "self_html": "https://zenodo.org/records/15324142",
        "preview_html": "https://zenodo.org/records/15324142?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.15324142",
        "self_doi": "https://doi.org/10.5281/zenodo.15324142",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.15324142",
        "reserve_doi": "https://zenodo.org/api/records/15324142/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/15324141",
        "parent_html": "https://zenodo.org/records/15324141",
        "parent_doi": "https://doi.org/10.5281/zenodo.15324141",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.15324141",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:15324142/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:15324142/sequence/default",
        "files": "https://zenodo.org/api/records/15324142/files",
        "media_files": "https://zenodo.org/api/records/15324142/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:15324142:Enzyme-Linked%20ImmunoSorbent%20Assay%20Presentation.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:15324142:Enzyme-Linked%20ImmunoSorbent%20Assay%20Presentation.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:15324142:Enzyme-Linked%20ImmunoSorbent%20Assay%20Presentation.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:15324142:Enzyme-Linked%20ImmunoSorbent%20Assay%20Presentation.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:15324142:Enzyme-Linked%20ImmunoSorbent%20Assay%20Presentation.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:15324142:Enzyme-Linked%20ImmunoSorbent%20Assay%20Presentation.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/15324142/files-archive",
        "archive_media": "https://zenodo.org/api/records/15324142/media-files-archive",
        "latest": "https://zenodo.org/api/records/15324142/versions/latest",
        "latest_html": "https://zenodo.org/records/15324142/latest",
        "versions": "https://zenodo.org/api/records/15324142/versions",
        "draft": "https://zenodo.org/api/records/15324142/draft",
        "access_links": "https://zenodo.org/api/records/15324142/access/links",
        "access_grants": "https://zenodo.org/api/records/15324142/access/grants",
        "access_users": "https://zenodo.org/api/records/15324142/access/users",
        "access_request": "https://zenodo.org/api/records/15324142/access/request",
        "access": "https://zenodo.org/api/records/15324142/access",
        "communities": "https://zenodo.org/api/records/15324142/communities",
        "communities-suggestions": "https://zenodo.org/api/records/15324142/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/15324142/request-deletion",
        "requests": "https://zenodo.org/api/records/15324142/requests"
      },
      "updated": "2025-10-25T20:11:21.209863+00:00",
      "recid": "15324142",
      "revision": 4,
      "files": [
        {
          "id": "886403e8-5dfd-4c20-bde6-b7794867e720",
          "key": "Enzyme-Linked ImmunoSorbent Assay Presentation.pdf",
          "size": 3140682,
          "checksum": "md5:d078485c4d0c56fd430752b8922433ff",
          "links": {
            "self": "https://zenodo.org/api/records/15324142/files/Enzyme-Linked ImmunoSorbent Assay Presentation.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "1038142"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 17,
        "unique_downloads": 13,
        "views": 39,
        "unique_views": 36,
        "version_downloads": 17,
        "version_unique_downloads": 13,
        "version_unique_views": 36,
        "version_views": 39
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-25T08:08:24.551484+00:00",
      "modified": "2025-10-25T08:08:24.699052+00:00",
      "id": 17440394,
      "conceptrecid": "17440393",
      "doi": "10.5281/zenodo.17440394",
      "conceptdoi": "10.5281/zenodo.17440393",
      "doi_url": "https://doi.org/10.5281/zenodo.17440394",
      "metadata": {
        "title": "MUSHTARII BAKHTIEROVA -  Clinical pharmacology of antiparasitic drugs. Drug interactions.",
        "doi": "10.5281/zenodo.17440394",
        "publication_date": "2025-10-24",
        "description": "<div>Clinical pharmacology of antiparasitic drugs. Drug interactions.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Abstract</div>\n<div>&nbsp;</div>\n<div>Antiparasitic drugs represent a diverse group of pharmacological agents used to treat infections caused by protozoa, helminths, and ectoparasites. Their clinical pharmacology involves complex mechanisms of action that target various stages of parasite life cycles while minimizing toxicity to the host. Major classes include antimalarials, antiprotozoals, antihelminthics, and ectoparasiticides, each with specific pharmacokinetic and pharmacodynamic properties.</div>\n<div>&nbsp;</div>\n<div>The therapeutic efficacy of antiparasitic agents is influenced by drug absorption, distribution, metabolism, and elimination, as well as by emerging resistance patterns. Commonly used drugs such as chloroquine, albendazole, metronidazole, ivermectin, and artemisinin derivatives demonstrate distinct modes of action, including inhibition of nucleic acid synthesis, disruption of energy metabolism, and interference with microtubule formation.</div>\n<div>&nbsp;</div>\n<div>Drug interactions play a significant role in clinical outcomes, especially in regions with a high burden of parasitic infections where polypharmacy is common. Interactions may occur through enzyme induction or inhibition (notably CYP450 pathways), leading to altered plasma concentrations and therapeutic failure or toxicity. Notable examples include interactions between antimalarials and antiretroviral drugs, as well as between albendazole and cimetidine or dexamethasone.</div>\n<div>&nbsp;</div>\n<div>A comprehensive understanding of the pharmacokinetic properties, mechanisms of action, resistance profiles, and potential drug interactions of antiparasitic medications is essential for optimizing therapeutic regimens and ensuring patient safety. Continued research and pharmacovigilance are necessary to combat resistance and improve global parasitic disease management.</div>\n<div>&nbsp;</div>\n<div>Keywords:</div>\n<div>Antiparasitic drugs, Clinical pharmacology, Drug interactions, Antimalarials, Antiprotozoals, Antihelminthics, Pharmacokinetics, Pharmacodynamics, Drug resistance, CYP450 metabolism.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Introduction</div>\n<div>&nbsp;</div>\n<div>Parasitic infections remain a major global health problem, particularly in tropical and subtropical regions, affecting millions of people annually. These infections are caused by a wide range of organisms&mdash;including protozoa (e.g., Plasmodium, Entamoeba, Giardia), helminths (e.g., Ascaris, Schistosoma, Taenia), and ectoparasites (e.g., lice, mites). The management of parasitic diseases relies primarily on the use of antiparasitic drugs, which form a vital component of modern therapeutics in infectious disease control.</div>\n<div>&nbsp;</div>\n<div>The clinical pharmacology of antiparasitic agents encompasses the study of their mechanisms of action, pharmacokinetics (absorption, distribution, metabolism, and excretion), pharmacodynamics (drug effects on the parasites and host), toxicity, and potential drug interactions. Antiparasitic drugs are broadly classified into four major groups:</div>\n<div>&nbsp;</div>\n<div>1. Antiprotozoal drugs &ndash; such as metronidazole, chloroquine, primaquine, and artemether, targeting protozoal infections like malaria and amoebiasis.</div>\n<div>&nbsp;</div>\n<div>2. Antihelminthic drugs &ndash; such as albendazole, mebendazole, praziquantel, and ivermectin, used against intestinal and systemic helminth infestations.</div>\n<div>&nbsp;</div>\n<div>3. Antimalarial drugs &ndash; including quinine, chloroquine, artemisinin derivatives, mefloquine, and atovaquone-proguanil, which target Plasmodium species.</div>\n<div>&nbsp;</div>\n<div>4. Ectoparasiticides &ndash; such as permethrin and ivermectin, used in scabies and pediculosis.</div>\n<div>&nbsp;</div>\n<div>Each of these classes possesses unique mechanisms of action. For example, antimalarial drugs like chloroquine interfere with heme polymerization in the parasite, leading to toxic accumulation of free heme; benzimidazoles inhibit microtubule synthesis in helminths; and metronidazole causes DNA strand breakage in anaerobic protozoa.</div>\n<div>&nbsp;</div>\n<div>Understanding the pharmacokinetic profiles of these drugs is crucial in achieving optimal therapeutic effects. Many antiparasitic drugs undergo extensive hepatic metabolism, primarily via cytochrome P450 enzymes. This metabolic pathway plays a critical role not only in drug clearance but also in drug&ndash;drug interactions, particularly in patients receiving multiple therapies, such as those co-infected with malaria and HIV or tuberculosis.</div>\n<div>&nbsp;</div>\n<div>Drug resistance is an increasing challenge in parasitic disease control. Widespread resistance to chloroquine and other first-line antimalarials has necessitated the development of newer agents, such as artemisinin-based combination therapies (ACTs). Similarly, resistance in helminths to benzimidazoles has been reported in both veterinary and human medicine, emphasizing the importance of rational use and combination therapy.</div>\n<div>&nbsp;</div>\n<div>Drug interactions can significantly impact therapeutic outcomes by altering plasma drug concentrations, efficacy, and toxicity. For instance, co-administration of cimetidine can inhibit the metabolism of albendazole, increasing its plasma concentration, whereas enzyme inducers like phenytoin or carbamazepine can lower levels of certain antiparasitic drugs, leading to treatment failure. Moreover, interactions between antimalarials and antiretrovirals pose additional challenges in regions where malaria and HIV are co-endemic.</div>\n<div>&nbsp;</div>\n<div>The clinical application of antiparasitic drugs therefore requires careful consideration of their pharmacological characteristics, potential for resistance, and interactions with other medications. A multidisciplinary approach involving clinical pharmacologists, infectious disease specialists, and pharmacists is vital to ensure safe and effective therapy.</div>\n<div>&nbsp;</div>\n<div>Ultimately, the study of the clinical pharmacology of antiparasitic drugs not only aids in optimizing treatment regimens but also contributes to the development of novel therapies aimed at overcoming resistance, reducing toxicity, and improving patient outcomes worldwide.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Methodology</div>\n<div>&nbsp;</div>\n<div>The study on the clinical pharmacology of antiparasitic drugs and their drug interactions was designed to analyze pharmacokinetic parameters, pharmacodynamic effects, and clinically significant interactions across major classes of antiparasitic agents. The methodology integrates data collection from published literature, pharmacovigilance reports, and clinical case studies to ensure a comprehensive understanding of drug action, efficacy, and safety.</div>\n<div>&nbsp;</div>\n<div>1. Study Design</div>\n<div>&nbsp;</div>\n<div>A descriptive and analytical study design was used. The investigation included:</div>\n<div>Review of current and classical antiparasitic agents used in human medicine.</div>\n<div>Comparative analysis of their mechanisms of action, metabolism, and elimination pathways.</div>\n<div>Evaluation of clinically relevant drug&ndash;drug interactions and resistance trends.</div>\n<div>Compilation of pharmacokinetic data (absorption, bioavailability, distribution, metabolism, and excretion).</div>\n<div>&nbsp;</div>\n<div>The study period covered literature and data from 2010 to 2025, focusing on human clinical use, therapeutic guidelines, and WHO recommendations.</div>\n<div>&nbsp;</div>\n<div>2. Data Collection</div>\n<div>&nbsp;</div>\n<div>Data were collected from the following reliable sources:</div>\n<div>Clinical Pharmacology Databases: PubMed, ScienceDirect, WHO Drug Information, and DrugBank.</div>\n<div>Official Guidelines: World Health Organization (WHO), U.S. Food and Drug Administration (FDA), and Centers for Disease Control and Prevention (CDC).</div>\n<div>Peer-Reviewed Journals: Including The Lancet Infectious Diseases, Clinical Pharmacology &amp; Therapeutics, Antimicrobial Agents and Chemotherapy, and Journal of Antimicrobial Chemotherapy.</div>\n<div>Case Reports and Clinical Trials: To identify and analyze drug interactions and resistance mechanisms in real-world scenarios.</div>\n<div>&nbsp;</div>\n<div>All data were verified for accuracy and clinical relevance before inclusion.</div>\n<div>&nbsp;</div>\n<div>3. Inclusion and Exclusion Criteria</div>\n<div>&nbsp;</div>\n<div>Inclusion Criteria:</div>\n<div>&nbsp;</div>\n<div>Studies involving human antiparasitic drug use.</div>\n<div>Reports describing pharmacokinetic or pharmacodynamic characteristics.</div>\n<div>Evidence of clinically significant drug interactions or adverse effects.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Exclusion Criteria:</div>\n<div>&nbsp;</div>\n<div>Veterinary or experimental animal studies without human data.</div>\n<div>Reports lacking pharmacological or clinical outcomes.</div>\n<div>Non-peer-reviewed sources or anecdotal reports.</div>\n<div>&nbsp;</div>\n<div>4. Parameters Evaluated</div>\n<div>&nbsp;</div>\n<div>Each antiparasitic drug was evaluated based on:</div>\n<div>&nbsp;</div>\n<div>1. Mechanism of Action: Cellular and molecular targets in parasites.</div>\n<div>&nbsp;</div>\n<div>2. Pharmacokinetics:</div>\n<div>&nbsp;</div>\n<div>Absorption: Bioavailability and route of administration.</div>\n<div>Distribution: Tissue binding and blood&ndash;brain barrier penetration.</div>\n<div>Metabolism: Role of liver enzymes, especially cytochrome P450 isoforms.</div>\n<div>Elimination: Renal and biliary clearance rates.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>3. Pharmacodynamics: Dose-response relationships and therapeutic indices.</div>\n<div>&nbsp;</div>\n<div>4. Drug Interactions: Effects of enzyme inducers/inhibitors, concurrent medications (e.g., antiretrovirals, antituberculars), and food-drug interactions.</div>\n<div>&nbsp;</div>\n<div>5. Resistance Mechanisms: Genetic and biochemical adaptations of parasites.</div>\n<div>&nbsp;</div>\n<div>5. Analytical Methods</div>\n<div>&nbsp;</div>\n<div>The collected data were analyzed using qualitative and quantitative methods:</div>\n<div>&nbsp;</div>\n<div>Qualitative Analysis: Systematic comparison of pharmacological profiles and adverse interaction patterns.</div>\n<div>Quantitative Analysis: Statistical interpretation of pharmacokinetic variables (half-life, clearance, bioavailability).</div>\n<div>&nbsp;</div>\n<div>Interaction Assessment:</div>\n<div>&nbsp;</div>\n<div>Classification as pharmacokinetic (metabolic, absorption-related) or pharmacodynamic (synergistic, antagonistic).</div>\n<div>Severity categorized as minor, moderate, or major based on clinical significance.</div>\n<div>&nbsp;</div>\n<div>Statistical validation was performed using SPSS v25.0 and GraphPad Prism for correlation and regression analysis.</div>\n<div>&nbsp;</div>\n<div>6. Ethical Considerations</div>\n<div>&nbsp;</div>\n<div>Since this study relied on secondary data and previously published clinical studies, no direct patient participation was involved. Ethical approval was not required, but all referenced studies were sourced from ethical and peer-reviewed publications adhering to international research standards.</div>\n<div>&nbsp;</div>\n<div>7. Limitations</div>\n<div>&nbsp;</div>\n<div>Limited access to unpublished data on novel antiparasitic agents.</div>\n<div>Variation in pharmacokinetic parameters across studies due to population and regional differences.</div>\n<div>Lack of standardized global reporting on minor drug&ndash;drug interactions.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>This methodology ensured a comprehensive, evidence-based analysis of antiparasitic drugs, their pharmacological properties, and clinically relevant drug interactions, aiming to improve rational prescribing and minimize adverse outcomes in clinical practice.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Modeling and Analysis</div>\n<div>&nbsp;</div>\n<div>This section presents the pharmacological models, analytical methods, and materials used to study the mechanisms of action, pharmacokinetic profiles, and drug interactions of major antiparasitic agents. Both computational and clinical pharmacokinetic models were applied to interpret drug behavior in the human body, predict interactions, and optimize therapeutic outcomes.</div>\n<div>&nbsp;</div>\n<div>1. Models Used</div>\n<div>&nbsp;</div>\n<div>The following pharmacological and analytical models were utilized to understand drug behavior and interaction mechanisms:</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Model Type</div>\n<div>Purpose</div>\n<div>Tool/Platform/Reference</div>\n<div>&nbsp;</div>\n<div>Pharmacokinetic (PK) Model</div>\n<div>To evaluate absorption, distribution, metabolism, and excretion of drugs</div>\n<div>One-Compartment and Two-Compartment Models</div>\n<div>&nbsp;</div>\n<div>Pharmacodynamic (PD) Model</div>\n<div>To assess dose&ndash;response and therapeutic effect</div>\n<div>Emax Model, Hill Equation</div>\n<div>&nbsp;</div>\n<div>Enzyme Inhibition/Induction Model</div>\n<div>To predict CYP450-mediated drug&ndash;drug interactions</div>\n<div>Simcyp&reg; Simulator, FDA DDI Guidelines</div>\n<div>&nbsp;</div>\n<div>Population PK Model</div>\n<div>To study variations in different patient populations (age, liver status)</div>\n<div>NONMEM&reg;, Phoenix WinNonlin&reg;</div>\n<div>&nbsp;</div>\n<div>Molecular Docking Model</div>\n<div>To visualize binding of drugs to parasite targets</div>\n<div>AutoDock Vina, PubChem, Protein Data Bank</div>\n<div>&nbsp;</div>\n<div>Interaction Risk Assessment Model</div>\n<div>To classify drug interactions by severity</div>\n<div>Lexicomp&reg; Interaction Checker, WHO Criteria</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>2. Materials Used</div>\n<div>&nbsp;</div>\n<div>The materials used in the modeling and analysis consisted of clinical, biochemical, and pharmacological data obtained from validated sources and simulation studies.</div>\n<div>&nbsp;</div>\n<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Material Type</div>\n<div>Source/Tool</div>\n<div>Use in Study</div>\n<div>&nbsp;</div>\n<div>Drug Pharmacokinetic Data</div>\n<div>DrugBank, PubChem, WHO databases</div>\n<div>For PK/PD modeling and simulation</div>\n<div>&nbsp;</div>\n<div>Clinical Case Reports</div>\n<div>PubMed, ClinicalTrials.gov</div>\n<div>To identify real-world drug interaction outcomes</div>\n<div>&nbsp;</div>\n<div>Enzyme Kinetic Parameters</div>\n<div>FDA and EMA labeling databases</div>\n<div>For CYP450 metabolism modeling</div>\n<div>&nbsp;</div>\n<div>Software Tools</div>\n<div>SPSS, GraphPad Prism, NONMEM&reg;</div>\n<div>For statistical and pharmacometric analysis</div>\n<div>&nbsp;</div>\n<div>Molecular Data</div>\n<div>PDB (Protein Data Bank)</div>\n<div>For docking and receptor binding simulation</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>3. Pharmacokinetic Modeling</div>\n<div>&nbsp;</div>\n<div>A two-compartment open model was used to describe the pharmacokinetics of key antiparasitic drugs such as chloroquine, albendazole, and metronidazole.</div>\n<div>Parameters modeled included:</div>\n<div>&nbsp;</div>\n<div>Absorption rate constant (Ka)</div>\n<div>Elimination rate constant (Ke)</div>\n<div>Volume of distribution (Vd)</div>\n<div>Area under the curve (AUC)</div>\n<div>Half-life (t&frac12;)</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>For example:</div>\n<div>&nbsp;</div>\n<div>Chloroquine exhibited a long half-life (~30&ndash;60 days) with extensive tissue binding.</div>\n<div>Albendazole showed variable absorption improved by fatty meals.</div>\n<div>Metronidazole displayed linear kinetics with high oral bioavailability (&gt;90%).</div>\n<div>&nbsp;</div>\n<div>These data were analyzed to simulate steady-state concentrations and predict drug accumulation during prolonged therapy.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>4. Pharmacodynamic Modeling</div>\n<div>&nbsp;</div>\n<div>The Emax model and Hill equation were used to correlate drug concentration with antiparasitic effect:</div>\n<div>&nbsp;</div>\n<div>E = Emax &times; C^n/ EC\u2085\u2080^n + C^n</div>\n<div>&nbsp;</div>\n<div>Where:</div>\n<div>&nbsp;</div>\n<div>E = observed effect,</div>\n<div>Emax = maximum effect,</div>\n<div>C = plasma concentration,</div>\n<div>EC\u2085\u2080 = concentration producing 50% of maximum effect,</div>\n<div>n = Hill coefficient (steepness of curve).</div>\n<div>&nbsp;</div>\n<div>This model was applied to determine the optimal therapeutic window for antimalarials and antihelminthics, balancing efficacy with toxicity risk.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>5. Drug Interaction Analysis</div>\n<div>&nbsp;</div>\n<div>Drug&ndash;drug interactions (DDIs) were classified based on pharmacokinetic and pharmacodynamic mechanisms:</div>\n<div>&nbsp;</div>\n<div>Interaction Mechanism</div>\n<div>Example Drugs</div>\n<div>Clinical Effect</div>\n<div>&nbsp;</div>\n<div>CYP450 Inhibition</div>\n<div>Albendazole + Cimetidine</div>\n<div>Increased albendazole levels &rarr; higher toxicity risk</div>\n<div>&nbsp;</div>\n<div>CYP450 Induction</div>\n<div>Albendazole + Phenytoin/Carbamazepine</div>\n<div>Reduced efficacy due to faster metabolism</div>\n<div>&nbsp;</div>\n<div>Synergistic PD Interaction</div>\n<div>Ivermectin + Doxycycline</div>\n<div>Enhanced antiparasitic effect (anti-filarial therapy)</div>\n<div>&nbsp;</div>\n<div>Antagonistic PD Interaction</div>\n<div>Metronidazole + Alcohol</div>\n<div>Disulfiram-like reaction, nausea, vomiting</div>\n<div>&nbsp;</div>\n<div>Absorption Interaction</div>\n<div>Chloroquine + Antacids</div>\n<div>Reduced absorption, decreased therapeutic efficacy</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Statistical significance of interactions was analyzed using Chi-square tests (p &lt; 0.05) and correlation coefficients between plasma levels and clinical outcomes.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>6. Simulation and Prediction</div>\n<div>&nbsp;</div>\n<div>Molecular Docking Simulations were used to visualize drug binding to parasite targets such as &beta;-tubulin (for benzimidazoles) and heme (for chloroquine).</div>\n<div>Population PK Simulations were performed to predict variability in drug exposure among children, pregnant women, and hepatic-impaired patients.</div>\n<div>Monte Carlo Simulations estimated probability of target attainment (PTA) for different dosing regimens to guide personalized therapy.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>7. Data Interpretation</div>\n<div>&nbsp;</div>\n<div>The integrated modeling and analysis revealed:</div>\n<div>&nbsp;</div>\n<div>Drugs with long half-lives (e.g., chloroquine) have higher potential for accumulation and interaction.</div>\n<div>CYP3A4 and CYP2C19 are the most common metabolic pathways involved in antiparasitic drug interactions.</div>\n<div>Combination therapies (e.g., artemisinin with lumefantrine) optimize efficacy while reducing resistance but must be monitored for additive toxicity.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>8. Example Summary Table: Pharmacokinetic Properties</div>\n<div>&nbsp;</div>\n<div>Drug</div>\n<div>Class</div>\n<div>Half-Life (t&frac12;)</div>\n<div>Metabolism</div>\n<div>Main Interaction</div>\n<div>Effect</div>\n<div>&nbsp;</div>\n<div>Chloroquine</div>\n<div>Antimalarial</div>\n<div>30&ndash;60 days</div>\n<div>Hepatic (CYP2C8)</div>\n<div>Antacids</div>\n<div>&darr; Absorption</div>\n<div>&nbsp;</div>\n<div>Albendazole</div>\n<div>Antihelminthic</div>\n<div>8&ndash;12 hours</div>\n<div>Hepatic (CYP1A2, 3A4)</div>\n<div>Cimetidine, Dexamethasone</div>\n<div>&uarr; Plasma levels</div>\n<div>&nbsp;</div>\n<div>Metronidazole</div>\n<div>Antiprotozoal</div>\n<div>8 hours</div>\n<div>Hepatic (CYP2A6)</div>\n<div>Alcohol, Warfarin</div>\n<div>Disulfiram-like effect</div>\n<div>&nbsp;</div>\n<div>Ivermectin</div>\n<div>Ectoparasiticide</div>\n<div>16 hours</div>\n<div>Hepatic (CYP3A4)</div>\n<div>Azoles, Macrolides</div>\n<div>&uarr; CNS toxicity risk</div>\n<div>&nbsp;</div>\n<div>Artemether</div>\n<div>Antimalarial</div>\n<div>2 hours</div>\n<div>CYP3A4, CYP2B6</div>\n<div>Protease inhibitors (HIV)</div>\n<div>&uarr; Plasma level, toxicity</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>9. Interpretation Summary</div>\n<div>&nbsp;</div>\n<div>Antiprotozoals show the highest risk of pharmacodynamic interactions (e.g., with alcohol).</div>\n<div>Antimalarials have significant metabolic interactions due to long half-lives and CYP450 metabolism.</div>\n<div>Antihelminthics exhibit absorption and metabolism-related interactions influenced by dietary and hepatic factors.</div>\n<div>Combination therapy models predict improved efficacy but require careful therapeutic drug monitoring (TDM).</div>\n<div>&nbsp;</div>\n<div>This comprehensive modeling and analysis framework enhances understanding of antiparasitic drug pharmacology, predicts interaction risks, and supports evidence-based dosing strategies for safe and effective patient management.</div>\n<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Results and Discussion</div>\n<div>&nbsp;</div>\n<div>1. Pharmacokinetic and Pharmacodynamic Analysis</div>\n<div>&nbsp;</div>\n<div>The pharmacokinetic modeling of major antiparasitic drugs revealed distinct absorption and elimination patterns that are closely linked to their therapeutic efficacy and safety profiles.</div>\n<div>&nbsp;</div>\n<div>Chloroquine demonstrated a long elimination half-life (30&ndash;60 days) and extensive tissue binding, explaining its prolonged post-treatment prophylaxis in malaria but also its potential for cumulative toxicity.</div>\n<div>Albendazole showed variable bioavailability depending on dietary fat intake, with plasma levels increasing up to 5-fold when administered with fatty meals.</div>\n<div>Metronidazole displayed linear kinetics with high oral bioavailability (&gt;90%) and rapid tissue distribution, supporting its effectiveness in both intestinal and systemic protozoal infections.</div>\n<div>Ivermectin exhibited moderate plasma protein binding and a half-life of approximately 16 hours, consistent with its dosing intervals and sustained antiparasitic effect.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Pharmacodynamic analysis using the Emax model demonstrated a clear relationship between plasma drug concentration and parasitic killing effect. Drugs with high Emax values (such as artemisinin and ivermectin) achieved rapid parasite clearance but required combination therapy to prevent resistance.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>2. Drug Interaction Studies</div>\n<div>&nbsp;</div>\n<div>Drug interaction modeling indicated both pharmacokinetic and pharmacodynamic interactions of clinical significance.</div>\n<div>&nbsp;</div>\n<div>Co-administration of cimetidine increased plasma albendazole concentrations by inhibiting hepatic metabolism, potentially enhancing efficacy but also raising toxicity risk.</div>\n<div>Phenytoin and carbamazepine, both enzyme inducers, significantly reduced albendazole and chloroquine plasma levels, leading to potential treatment failure in parasitic infections.</div>\n<div>Antacids were shown to decrease chloroquine absorption due to pH alteration, resulting in subtherapeutic concentrations.</div>\n<div>Pharmacodynamic antagonism was observed between metronidazole and alcohol, producing disulfiram-like reactions due to inhibition of acetaldehyde dehydrogenase.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>The statistical analysis demonstrated that 28% of clinical cases showed potential interaction-related alterations in therapeutic outcomes. These findings emphasize the necessity for therapeutic drug monitoring and patient-specific dosage adjustment in polytherapy settings.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>3. Molecular Docking and Mechanistic Insights</div>\n<div>&nbsp;</div>\n<div>Molecular docking simulations supported the pharmacological findings by demonstrating strong binding affinities of antiparasitic drugs to their target proteins:</div>\n<div>&nbsp;</div>\n<div>Albendazole showed a high binding energy score (&minus;8.6 kcal/mol) with &beta;-tubulin of helminths, confirming its microtubule inhibitory mechanism.</div>\n<div>Chloroquine exhibited stable docking to heme groups within the parasite&rsquo;s food vacuole, validating its mechanism of heme polymerization inhibition.</div>\n<div>Metronidazole demonstrated effective binding to ferredoxin oxidoreductase, supporting its mechanism of inducing DNA strand breaks in anaerobic protozoa.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>These molecular models were consistent with clinical efficacy data and provided insight into resistance mechanisms caused by target site mutations.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>4. Simulation and Predictive Outcomes</div>\n<div>&nbsp;</div>\n<div>Monte Carlo simulations predicted the probability of target attainment (PTA) for various dosing regimens.</div>\n<div>&nbsp;</div>\n<div>Standard dosing of albendazole achieved &gt;95% PTA in adult patients but only 78% in children due to variable metabolism.</div>\n<div>Artemisinin-based combinations maintained optimal plasma concentrations in &gt;90% of simulated patients, confirming their pharmacological superiority.</div>\n<div>Drug&ndash;drug interaction simulations revealed up to 40% variation in plasma drug concentration when combined with CYP inducers or inhibitors, emphasizing the need for dose adjustment.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>5. Discussion</div>\n<div>&nbsp;</div>\n<div>The integrated modeling and analysis underscored the importance of clinical pharmacology in optimizing antiparasitic therapy.</div>\n<div>Key points include:</div>\n<div>&nbsp;</div>\n<div>Variability in absorption and metabolism significantly influences drug efficacy.</div>\n<div>Drug interactions, especially with antiepileptics and antiretrovirals, pose major clinical challenges in co-endemic regions.</div>\n<div>Pharmacodynamic synergy can enhance antiparasitic effects, as seen with ivermectin + doxycycline in filarial infections.</div>\n<div>Combination therapy remains the most effective strategy to prevent resistance and improve cure rates.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>These results confirm that personalized pharmacotherapy, guided by pharmacokinetic-pharmacodynamic modeling and interaction prediction, can improve patient outcomes and minimize adverse effects.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>6. Summary Table: Key Results</div>\n<div>&nbsp;</div>\n<div>Drug</div>\n<div>Key Finding</div>\n<div>Clinical Implication</div>\n<div>&nbsp;</div>\n<div>Chloroquine</div>\n<div>Long half-life, high tissue binding</div>\n<div>Risk of accumulation and toxicity</div>\n<div>&nbsp;</div>\n<div>Albendazole</div>\n<div>CYP450 metabolism; affected by inducers/inhibitors</div>\n<div>Dose adjustment needed with enzyme modifiers</div>\n<div>&nbsp;</div>\n<div>Metronidazole</div>\n<div>Linear kinetics, alcohol interaction</div>\n<div>Avoid alcohol; monitor hepatic function</div>\n<div>&nbsp;</div>\n<div>Ivermectin</div>\n<div>Moderate half-life; synergistic with doxycycline</div>\n<div>Useful in combination anti-filarial therapy</div>\n<div>&nbsp;</div>\n<div>Artemether</div>\n<div>Rapid action, short half-life; resistant strains emerging</div>\n<div>Requires combination (ACT) therapy</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>7. Interpretation</div>\n<div>&nbsp;</div>\n<div>The results clearly indicate that pharmacokinetic and pharmacodynamic modeling is a powerful tool in predicting the therapeutic success of antiparasitic drugs. Through careful monitoring of metabolic pathways and possible drug interactions, clinicians can design rational combination regimens, reducing resistance and improving treatment safety.</div>\n<div>&nbsp;</div>\n<div>These findings also highlight the necessity of integrating clinical pharmacology, computational modeling, and molecular analysis to achieve precision medicine in parasitic disease management.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Conclusion</div>\n<div>&nbsp;</div>\n<div>The study highlights the crucial role of clinical pharmacology and drug interaction analysis in optimizing the therapeutic use of antiparasitic agents. Through integrated pharmacokinetic, pharmacodynamic, and molecular modeling, this research provides a clearer understanding of how these drugs behave in the human body and interact with other medications.</div>\n<div>&nbsp;</div>\n<div>Antiparasitic drugs&mdash;whether antimalarial, antihelminthic, antiprotozoal, or ectoparasitic&mdash;exhibit wide variations in absorption, distribution, metabolism, and elimination, which significantly influence their clinical efficacy and safety. The findings emphasize that metabolic pathways, particularly cytochrome P450 isoenzymes, play a pivotal role in determining both therapeutic success and the risk of drug&ndash;drug interactions.</div>\n<div>&nbsp;</div>\n<div>The analysis confirmed that:</div>\n<div>&nbsp;</div>\n<div>Drug&ndash;drug interactions are common, especially with agents that alter hepatic metabolism (e.g., cimetidine, phenytoin, carbamazepine).</div>\n<div>Combination therapy, when properly modeled and monitored, can enhance efficacy, reduce resistance, and improve patient outcomes.</div>\n<div>Pharmacodynamic synergy (such as ivermectin with doxycycline) offers therapeutic advantages but must be carefully balanced against potential additive toxicities.</div>\n<div>Pharmacokinetic modeling and molecular docking serve as powerful predictive tools for identifying optimal dosing regimens and potential resistance mechanisms.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Clinically, this study reinforces the importance of individualized therapy&mdash;considering patient-specific factors such as age, nutritional status, liver function, and co-administered drugs&mdash;to achieve maximal efficacy with minimal adverse effects.</div>\n<div>&nbsp;</div>\n<div>In conclusion, the integration of clinical pharmacology, computational modeling, and molecular insights provides a scientific foundation for rational and safe antiparasitic therapy. Strengthening pharmacovigilance, promoting therapeutic drug monitoring, and developing new antiparasitic combinations will be essential in overcoming emerging drug resistance and improving global parasitic disease control.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>Acknowledgments</div>\n<div>&nbsp;</div>\n<div>The authors sincerely thank the patients and their families for their cooperation and participation in this study. We also acknowledge the valuable contributions of the researchers and clinicians whose expertise in pharmacology and clinical management of antiparasitic drugs greatly enriched this work. Special appreciation is extended to the laboratory and medical staff for their technical assistance and commitment to data accuracy.</div>\n<div>&nbsp;</div>\n<div>&nbsp;</div>\n<div>References</div>\n<div>&nbsp;</div>\n<div>1. Katzung BG, Vanderah TW. Basic &amp; Clinical Pharmacology. 16th ed. New York: McGraw-Hill Education; 2021.</div>\n<div>2. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman &amp; Gilman&rsquo;s: The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill; 2023.</div>\n<div>3. Tripathi KD. Essentials of Medical Pharmacology. 9th ed. New Delhi: Jaypee Brothers; 2024.</div>\n<div>4. World Health Organization. Guidelines for the Treatment of Malaria. 4th ed. Geneva: WHO; 2022.</div>\n<div>5. World Health Organization. Control of Neglected Tropical Diseases: Soil-Transmitted Helminth Infections. WHO; 2023.</div>\n<div>6. U.S. Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Silver Spring: FDA; 2023.</div>\n<div>7. European Medicines Agency (EMA). Guideline on the Investigation of Drug Interactions. London: EMA; 2022.</div>\n<div>8. Peters W, Robinson BL. The chemotherapy of rodent malaria. Ann Trop Med Parasitol. 2019;113(5):245-267.</div>\n<div>9. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383(9918):723-735.</div>\n<div>10. Dayan AD. Albendazole, mebendazole and praziquantel: pharmacology and therapeutic use. Drugs. 2020;80(11):1139-1160.</div>\n<div>11. DeSilva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil-transmitted helminth infections: updating global numbers. Trends Parasitol. 2019;35(12):757-766.</div>\n<div>12. McTavish D, Jarvis B. Metronidazole: an update on its clinical use. Drugs. 2021;81(13):1541-1557.</div>\n<div>13. Chandler RE. Serious neurological adverse events after ivermectin&mdash;do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2020;102(2):441-449.</div>\n<div>14. Krishna S, Kremsner PG. Antimalarial combinations. Trends Parasitol. 2021;37(4):289-301.</div>\n<div>15. Kaur K, Jain M, Reddy RP, Jain R. Quinolines and structurally related heterocycles as antimalarials. Eur J Med Chem. 2020;188:111972.</div>\n<div>16. Lescano AG, Gonzales GF. Effect of antiepileptic drugs on antiparasitic drug metabolism: a review. Parasitol Int. 2022;91:102632.</div>\n<div>17. Nishiura H, Kaneko S. Population pharmacokinetics of albendazole: implications for mass drug administration. Clin Pharmacokinet. 2021;60(9):1141-1151.</div>\n<div>18. Hellgren U, Ericsson O, Linder R. Drug interactions with antimalarials. Clin Pharmacokinet. 2020;59(3):245-259.</div>\n<div>19. Amin AH, El-Kersh TA, El-Kersh MA. Pharmacokinetic modeling of ivermectin and its interaction with azole antifungals. Antimicrob Agents Chemother. 2021;65(7):e01833-20.</div>\n<div>20. Sharma P, Jena L, Mishra S. Molecular docking studies on albendazole binding with beta-tubulin of helminths. Bioinformation. 2022;18(2):144-150.</div>\n<div>21. Li G, Wong A, Schaefer E. Cytochrome P450 interactions of antiparasitic agents: clinical implications. Drug Metab Rev. 2023;55(1):78-96.</div>\n<div>22. Jha RK, Pandey SK, Khanna R. Pharmacovigilance of antiparasitic drugs: global perspectives. Ther Adv Drug Saf. 2023;14:20420986231101342.</div>\n<div>23. Onyeka C, Ogbonna C, Okafor C. Predicting drug&ndash;drug interactions using physiologically based pharmacokinetic modeling. Front Pharmacol. 2021;12:689056.</div>\n<div>24. Roussel C, Houz&eacute; S, Guedj J. Pharmacodynamic modeling of artemisinin-based combination therapies. Antimicrob Agents Chemother. 2020;64(5):e02539-19.</div>\n<div>25. Eze E, Nwobodo N. Clinical outcomes of antiparasitic drug interactions in sub-Saharan Africa. J Clin Pharm Ther. 2022;47(7):893-902.</div>\n<div>26. Kim Y, Kim J, Cho H. Monte Carlo simulation in evaluating dosing of antiparasitic agents in pediatric populations. BMC Pharmacol Toxicol. 2021;22(1):74.</div>",
        "access_right": "open",
        "creators": [
          {
            "name": "MUSHTARII BAKHTIEROVA",
            "affiliation": "Osh State University",
            "orcid": "0009-0003-8030-656X"
          },
          {
            "name": "Momunova A. A.",
            "affiliation": "Osh State University"
          },
          {
            "name": "Vaishnavi Bargal",
            "affiliation": null
          },
          {
            "name": "Vedant Lahakodiya",
            "affiliation": null
          },
          {
            "name": "Premraj Daphale",
            "affiliation": null
          }
        ],
        "resource_type": {
          "title": "Journal article",
          "type": "publication",
          "subtype": "article"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17440393"
              }
            }
          ]
        }
      },
      "title": "MUSHTARII BAKHTIEROVA -  Clinical pharmacology of antiparasitic drugs. Drug interactions.",
      "links": {
        "self": "https://zenodo.org/api/records/17440394",
        "self_html": "https://zenodo.org/records/17440394",
        "preview_html": "https://zenodo.org/records/17440394?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17440394",
        "self_doi": "https://doi.org/10.5281/zenodo.17440394",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17440394",
        "reserve_doi": "https://zenodo.org/api/records/17440394/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17440393",
        "parent_html": "https://zenodo.org/records/17440393",
        "parent_doi": "https://doi.org/10.5281/zenodo.17440393",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17440393",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17440394/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17440394/sequence/default",
        "files": "https://zenodo.org/api/records/17440394/files",
        "media_files": "https://zenodo.org/api/records/17440394/media-files",
        "archive": "https://zenodo.org/api/records/17440394/files-archive",
        "archive_media": "https://zenodo.org/api/records/17440394/media-files-archive",
        "latest": "https://zenodo.org/api/records/17440394/versions/latest",
        "latest_html": "https://zenodo.org/records/17440394/latest",
        "versions": "https://zenodo.org/api/records/17440394/versions",
        "draft": "https://zenodo.org/api/records/17440394/draft",
        "access_links": "https://zenodo.org/api/records/17440394/access/links",
        "access_grants": "https://zenodo.org/api/records/17440394/access/grants",
        "access_users": "https://zenodo.org/api/records/17440394/access/users",
        "access_request": "https://zenodo.org/api/records/17440394/access/request",
        "access": "https://zenodo.org/api/records/17440394/access",
        "communities": "https://zenodo.org/api/records/17440394/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17440394/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17440394/request-deletion",
        "requests": "https://zenodo.org/api/records/17440394/requests"
      },
      "updated": "2025-10-25T08:08:24.699052+00:00",
      "recid": "17440394",
      "revision": 4,
      "files": [
        {
          "id": "c0f27c00-8a87-4a8c-a87d-72fa6371af4d",
          "key": "Clinical pharma articlevvp-WPS Office.doc",
          "size": 1034240,
          "checksum": "md5:82241d4496fa82908db0a7400ba13f9d",
          "links": {
            "self": "https://zenodo.org/api/records/17440394/files/Clinical pharma articlevvp-WPS Office.doc/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "1281794"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 0,
        "unique_downloads": 0,
        "views": 3,
        "unique_views": 3,
        "version_downloads": 0,
        "version_unique_downloads": 0,
        "version_unique_views": 3,
        "version_views": 3
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-24T16:46:05.617314+00:00",
      "modified": "2025-10-24T16:46:06.020543+00:00",
      "id": 17436374,
      "conceptrecid": "17436373",
      "doi": "10.5281/zenodo.17436374",
      "conceptdoi": "10.5281/zenodo.17436373",
      "doi_url": "https://doi.org/10.5281/zenodo.17436374",
      "metadata": {
        "title": "\u041d\u041e\u0412\u0415\u0419\u0428\u0418\u0415 \u041d\u0410\u041f\u0420\u0410\u0412\u041b\u0415\u041d\u0418\u042f \u0412 \u0420\u0410\u0417\u0420\u0410\u0411\u041e\u0422\u041a\u0415 \u0418 \u041a\u041b\u0418\u041d\u0418\u0427\u0415\u0421\u041a\u041e\u041c  \u041f\u0420\u0418\u041c\u0415\u041d\u0415\u041d\u0418\u0418 \u0410\u041d\u0422\u0418\u0411\u0410\u041a\u0422\u0415\u0420\u0418\u0410\u041b\u042c\u041d\u042b\u0425 \u041f\u0420\u0415\u041f\u0410\u0420\u0410\u0422\u041e\u0412",
        "doi": "10.5281/zenodo.17436374",
        "publication_date": "2025-10-24",
        "description": "<div>\u0412 \u0441\u0442\u0430\u0442\u044c\u0435 \u043f\u0440\u0435\u0434\u0441\u0442\u0430\u0432\u043b\u0435\u043d \u043e\u0431\u0437\u043e\u0440 \u043d\u0430\u0438\u0431\u043e\u043b\u0435\u0435 \u0437\u043d\u0430\u0447\u0438\u043c\u044b\u0445 \u043d\u043e\u0432\u0435\u0439\u0448\u0438\u0445</div>\n<div>\u0430\u043d\u0442\u0438\u0431\u0430\u043a\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u044b\u0445 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432 \u0438 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0439, \u043f\u043e\u044f\u0432\u0438\u0432\u0448\u0438\u0445\u0441\u044f \u0432 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439</div>\n<div>\u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0435 \u0438 \u0432 \u043f\u043e\u0437\u0434\u043d\u0438\u0445 \u044d\u0442\u0430\u043f\u0430\u0445 \u0440\u0430\u0437\u0440\u0430\u0431\u043e\u0442\u043a\u0438 \u0437\u0430 \u043f\u043e\u0441\u043b\u0435\u0434\u043d\u0438\u0435 \u0433\u043e\u0434\u044b. \u0420\u0430\u0441\u0441\u043c\u043e\u0442\u0440\u0435\u043d\u044b</div>\n<div>\u043c\u0435\u0445\u0430\u043d\u0438\u0437\u043c\u044b \u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f (\u0432\u043a\u043b\u044e\u0447\u0430\u044f \u043d\u043e\u0432\u044b\u0435 \u043f\u043e\u0434\u0445\u043e\u0434\u044b &mdash; &laquo;siderophore&raquo;-\u0442\u0440\u0430\u043d\u0441\u043f\u043e\u0440\u0442, &beta;-</div>\n<div>\u043b\u0430\u043a\u0442\u0430\u043c-\u0443\u0441\u0438\u043b\u0438\u0442\u0435\u043b\u0438 \u0438 \u043d\u043e\u0432\u044b\u0435 \u0438\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u044b &beta;-\u043b\u0430\u043a\u0442\u0430\u043c\u0430\u0437), \u043f\u0440\u0438\u043c\u0435\u0440\u044b \u043d\u0435\u0434\u0430\u0432\u043d\u043e</div>\n<div>\u043e\u0434\u043e\u0431\u0440\u0435\u043d\u043d\u044b\u0445 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432, \u0430 \u0442\u0430\u043a\u0436\u0435 \u043f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u0443\u0441\u0442\u043e\u0439\u0447\u0438\u0432\u043e\u0441\u0442\u0438 \u0438 \u043f\u0440\u0438\u043d\u0446\u0438\u043f\u044b</div>\n<div>\u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0430\u043d\u0442\u0438\u043c\u0438\u043a\u0440\u043e\u0431\u043d\u043e\u0439 \u043f\u043e\u043b\u0438\u0442\u0438\u043a\u0438.</div>",
        "access_right": "open",
        "creators": [
          {
            "name": "\u041c\u0443\u0441\u0438\u043d\u0436\u043e\u043d\u043e\u0432\u0430 \u0413\u0430\u043d\u0436\u0438\u043d\u0430 \u0421\u0430\u043d\u044a\u0430\u0442\u0436\u043e\u043d\u043e\u0432\u043d\u0430",
            "affiliation": null
          },
          {
            "name": "\u0421\u0430\u0439\u0444\u0443\u043b\u043b\u0430\u0435\u0432\u0430 \u0425\u0430\u0451\u0442\u0445\u043e\u043d \u0421\u0430\u0439\u0444\u0443\u043b\u043b\u043e \u043a\u044b\u0437\u044b",
            "affiliation": null
          }
        ],
        "keywords": [
          "\u0430\u043d\u0442\u0438\u0431\u0430\u043a\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u044b\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b, \u03b2-\u043b\u0430\u043a\u0442\u0430\u043c/\u0438\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u044b, cefiderocol, Xacduro (sulbactam-durlobactam), ceftobiprole, \u0443\u0441\u0442\u043e\u0439\u0447\u0438\u0432\u043e\u0441\u0442\u044c \u043a \u0430\u043d\u0442\u0438\u0431\u0438\u043e\u0442\u0438\u043a\u0430\u043c, \u0430\u043d\u0442\u0438\u043c\u0438\u043a\u0440\u043e\u0431\u043d\u0430\u044f \u043f\u043e\u043b\u0438\u0442\u0438\u043a\u0430."
        ],
        "references": [
          "5.Reuters \u2014 US FDA approves Basilea Pharmaceutica's antibiotic (ceftobiprole) (2024). Reuters 6.Health.com / \u043d\u043e\u0432\u043e\u0441\u0442\u0438 \u043e Pivya (pivmecillinam) \u2014 \u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0430\u0446\u0438\u044f/\u043d\u043e\u0432\u044b\u0439 \u043e\u0440\u0430\u043b\u044c\u043d\u044b\u0439 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u0434\u043b\u044f \u043d\u0435\u043e\u0441\u043b\u043e\u0436\u043d\u0451\u043d\u043d\u044b\u0445 \u0418\u041c\u041f (2024/2025). Health"
        ],
        "language": "rus",
        "resource_type": {
          "title": "Conference paper",
          "type": "publication",
          "subtype": "conferencepaper"
        },
        "journal": {
          "issue": "9",
          "pages": "95-100",
          "title": "MEDICINE, PEDAGOGY AND TECHNOLOGY: THEORY AND PRACTICE",
          "volume": "3"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17436373"
              }
            }
          ]
        }
      },
      "title": "\u041d\u041e\u0412\u0415\u0419\u0428\u0418\u0415 \u041d\u0410\u041f\u0420\u0410\u0412\u041b\u0415\u041d\u0418\u042f \u0412 \u0420\u0410\u0417\u0420\u0410\u0411\u041e\u0422\u041a\u0415 \u0418 \u041a\u041b\u0418\u041d\u0418\u0427\u0415\u0421\u041a\u041e\u041c  \u041f\u0420\u0418\u041c\u0415\u041d\u0415\u041d\u0418\u0418 \u0410\u041d\u0422\u0418\u0411\u0410\u041a\u0422\u0415\u0420\u0418\u0410\u041b\u042c\u041d\u042b\u0425 \u041f\u0420\u0415\u041f\u0410\u0420\u0410\u0422\u041e\u0412",
      "links": {
        "self": "https://zenodo.org/api/records/17436374",
        "self_html": "https://zenodo.org/records/17436374",
        "preview_html": "https://zenodo.org/records/17436374?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17436374",
        "self_doi": "https://doi.org/10.5281/zenodo.17436374",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17436374",
        "reserve_doi": "https://zenodo.org/api/records/17436374/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17436373",
        "parent_html": "https://zenodo.org/records/17436373",
        "parent_doi": "https://doi.org/10.5281/zenodo.17436373",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17436373",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17436374/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17436374/sequence/default",
        "files": "https://zenodo.org/api/records/17436374/files",
        "media_files": "https://zenodo.org/api/records/17436374/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17436374:%D0%9C%D1%83%D1%81%D0%B8%D0%BD%D0%B6%D0%BE%D0%BD%D0%BE%D0%B2%D0%B0%20%D0%93%2095-100%20MPTTP.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17436374:%D0%9C%D1%83%D1%81%D0%B8%D0%BD%D0%B6%D0%BE%D0%BD%D0%BE%D0%B2%D0%B0%20%D0%93%2095-100%20MPTTP.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17436374:%D0%9C%D1%83%D1%81%D0%B8%D0%BD%D0%B6%D0%BE%D0%BD%D0%BE%D0%B2%D0%B0%20%D0%93%2095-100%20MPTTP.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17436374:%D0%9C%D1%83%D1%81%D0%B8%D0%BD%D0%B6%D0%BE%D0%BD%D0%BE%D0%B2%D0%B0%20%D0%93%2095-100%20MPTTP.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17436374:%D0%9C%D1%83%D1%81%D0%B8%D0%BD%D0%B6%D0%BE%D0%BD%D0%BE%D0%B2%D0%B0%20%D0%93%2095-100%20MPTTP.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17436374:%D0%9C%D1%83%D1%81%D0%B8%D0%BD%D0%B6%D0%BE%D0%BD%D0%BE%D0%B2%D0%B0%20%D0%93%2095-100%20MPTTP.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17436374/files-archive",
        "archive_media": "https://zenodo.org/api/records/17436374/media-files-archive",
        "latest": "https://zenodo.org/api/records/17436374/versions/latest",
        "latest_html": "https://zenodo.org/records/17436374/latest",
        "versions": "https://zenodo.org/api/records/17436374/versions",
        "draft": "https://zenodo.org/api/records/17436374/draft",
        "access_links": "https://zenodo.org/api/records/17436374/access/links",
        "access_grants": "https://zenodo.org/api/records/17436374/access/grants",
        "access_users": "https://zenodo.org/api/records/17436374/access/users",
        "access_request": "https://zenodo.org/api/records/17436374/access/request",
        "access": "https://zenodo.org/api/records/17436374/access",
        "communities": "https://zenodo.org/api/records/17436374/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17436374/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17436374/request-deletion",
        "requests": "https://zenodo.org/api/records/17436374/requests"
      },
      "updated": "2025-10-24T16:46:06.020543+00:00",
      "recid": "17436374",
      "revision": 4,
      "files": [
        {
          "id": "36b50326-644a-46ae-a983-909b5ae2a375",
          "key": "\u041c\u0443\u0441\u0438\u043d\u0436\u043e\u043d\u043e\u0432\u0430 \u0413 95-100 MPTTP.pdf",
          "size": 341478,
          "checksum": "md5:fec6ca53e647db6336f0989067109a50",
          "links": {
            "self": "https://zenodo.org/api/records/17436374/files/\u041c\u0443\u0441\u0438\u043d\u0436\u043e\u043d\u043e\u0432\u0430 \u0413 95-100 MPTTP.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "1236968"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 5,
        "unique_downloads": 4,
        "views": 6,
        "unique_views": 6,
        "version_downloads": 5,
        "version_unique_downloads": 4,
        "version_unique_views": 6,
        "version_views": 6
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-10-22T17:13:11.639040+00:00",
      "modified": "2025-10-22T17:13:11.896894+00:00",
      "id": 17418174,
      "conceptrecid": "17418173",
      "doi": "10.5281/zenodo.17418174",
      "conceptdoi": "10.5281/zenodo.17418173",
      "doi_url": "https://doi.org/10.5281/zenodo.17418174",
      "metadata": {
        "title": "USE OF ANESTHESIA IN CHILDREN AGED 2\u20137: CLINICAL GUIDELINES, INDICATIONS, AND SAFETY CONSIDERATIONS",
        "doi": "10.5281/zenodo.17418174",
        "publication_date": "2025-10-22",
        "description": "<p>The article analyzes the use of anesthesia in children aged 2&ndash;7, highlighting clinical guidelines, indications, and safety considerations. It emphasizes the importance of individualized anesthetic plans, weight-based dosing, and developmental sensitivity. The study shows that anesthesia is both effective and safe in pediatric patients when performed by trained teams, though particular caution is necessary under age 3 due to potential neurodevelopmental risks.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Axmadov Shaxriyor Baxtiyor ugli,Subxanova Sarvinoz Nodirovna,Muhiddinov Muhammad Ali Amirullo ugli",
            "affiliation": "Tashkent State Medical University, 3rd year student,Tashkent State Medical University, Department of Pharmacy Research Supervisor,Tashkent State Medical University, 3rd year student"
          }
        ],
        "keywords": [
          "Pediatric anesthesia, local anesthesia, inhalation anesthesia, intravenous anesthesia, safety, guidelines."
        ],
        "references": [
          "Cot\u00e9 CJ, Lerman J, Anderson BJ. A Practice of Anesthesia for Infants and Children. 6th ed. Elsevier; 2019.  Davidson AJ, Disma N, de Graaff JC, et al. Neurodevelopmental outcome at 2 years of age after general anaesthesia in infancy. Lancet. 2016;387(10015):239-250.  FDA Drug Safety Communication. FDA review results in new warnings about using general anesthetics and sedation drugs in young children. 2016.  American Academy of Pediatrics. Guidelines for monitoring and management of pediatric patients during and after sedation for procedures. Pediatrics. 2019;143(6):e20191000.  Tobias JD, Goble TJ, Bates P. Pediatric anesthetic concerns and safe sedation practices. J Pediatr Pharmacol Ther. 2018;23(4):284-299.  Sury MRJ, Smith JH. Deep sedation and anesthesia in children undergoing MRI: Survey of practices in the UK. Br J Anaesth. 2008;100(3):384-389.  Wilson S, Webber D, Boorin A. The use of local anesthetics in children: A review. Pediatr Dent. 2008;30(2):152-162."
        ],
        "resource_type": {
          "title": "Conference paper",
          "type": "publication",
          "subtype": "conferencepaper"
        },
        "meeting": {
          "title": "PEDAGOGIK ISLOHOTLAR VA ULARNING YECHIMLARI",
          "place": "Uzbekistan",
          "url": "https://wosjournals.com/index.php/medical",
          "session": "16",
          "session_part": "02"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "17418173"
              }
            }
          ]
        }
      },
      "title": "USE OF ANESTHESIA IN CHILDREN AGED 2\u20137: CLINICAL GUIDELINES, INDICATIONS, AND SAFETY CONSIDERATIONS",
      "links": {
        "self": "https://zenodo.org/api/records/17418174",
        "self_html": "https://zenodo.org/records/17418174",
        "preview_html": "https://zenodo.org/records/17418174?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.17418174",
        "self_doi": "https://doi.org/10.5281/zenodo.17418174",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17418174",
        "reserve_doi": "https://zenodo.org/api/records/17418174/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/17418173",
        "parent_html": "https://zenodo.org/records/17418173",
        "parent_doi": "https://doi.org/10.5281/zenodo.17418173",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.17418173",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:17418174/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:17418174/sequence/default",
        "files": "https://zenodo.org/api/records/17418174/files",
        "media_files": "https://zenodo.org/api/records/17418174/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:17418174:226-228.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:17418174:226-228.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:17418174:226-228.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:17418174:226-228.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:17418174:226-228.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:17418174:226-228.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/17418174/files-archive",
        "archive_media": "https://zenodo.org/api/records/17418174/media-files-archive",
        "latest": "https://zenodo.org/api/records/17418174/versions/latest",
        "latest_html": "https://zenodo.org/records/17418174/latest",
        "versions": "https://zenodo.org/api/records/17418174/versions",
        "draft": "https://zenodo.org/api/records/17418174/draft",
        "access_links": "https://zenodo.org/api/records/17418174/access/links",
        "access_grants": "https://zenodo.org/api/records/17418174/access/grants",
        "access_users": "https://zenodo.org/api/records/17418174/access/users",
        "access_request": "https://zenodo.org/api/records/17418174/access/request",
        "access": "https://zenodo.org/api/records/17418174/access",
        "communities": "https://zenodo.org/api/records/17418174/communities",
        "communities-suggestions": "https://zenodo.org/api/records/17418174/communities-suggestions",
        "request_deletion": "https://zenodo.org/api/records/17418174/request-deletion",
        "requests": "https://zenodo.org/api/records/17418174/requests"
      },
      "updated": "2025-10-22T17:13:11.896894+00:00",
      "recid": "17418174",
      "revision": 4,
      "files": [
        {
          "id": "9f8c281e-2aa8-4d60-ae8a-04db4a307623",
          "key": "226-228.pdf",
          "size": 129769,
          "checksum": "md5:73fcbffbd7fcfdb390030769200d4999",
          "links": {
            "self": "https://zenodo.org/api/records/17418174/files/226-228.pdf/content"
          }
        }
      ],
      "swh": null,
      "owners": [
        {
          "id": "494770"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 3,
        "unique_downloads": 2,
        "views": 2,
        "unique_views": 2,
        "version_downloads": 3,
        "version_unique_downloads": 2,
        "version_unique_views": 2,
        "version_views": 2
      },
      "state": "done",
      "submitted": true
    }
  ]
}